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PREFACE
The Tufts University School of Veterinary Medicine, Center for Animals and Public
Policy, sponsored an invitational seminar, The Value and Utility of Animals in
Research, on October 14, 1993, at the Hyatt Regency Hotel in Baltimore, Maryland.
This seminar was the second in a series of three organized by the Center for
Animals and Public Policy and supported by The Pew Charitable Trusts to deal with
issues relating to the use of animals in research. The first seminar, Biology
Education and Animals: Opportunities and Issues, was held in the spring of 1993.
The third meeting, at the National Press Club in Washington, D.C., on March 2,
1994, coincided with the Center's release of The Animal Research Controversy,
Protest, Process and Public Policy, an in-depth report prepared by the Center on the
status of research animals.
For this second seminar on the usefulness of animals in research, the Center
brought together twenty reprr?sentatives of animal protection organizations, animal
welfare publications and universities as well as medical historians and defenders of
animal research. The intent of this seminar was not to debate the moral questions
involved, but to examine the technical arguments being put forth by animal
activists and their opponents about the value (or lack of value) of animal use in
research.
This publication is produced by the Tufts Center for Animals and Public Policy and
the contents do not necessarily represent the views or opinions of all who attended
the seminar. Speakers had the opportunity to review and correct presentations and
comments attributed to them before completion of the final draft. A synopsis of
each discussion period is included although the identities of the questioners and
commentors are not necessarily provided.

Funding for the critique was provided in part by Working for Animals Used in
Research, Drugs and Surgery (WARDS).
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WELCOME AND INTRODUCTION
Franklin M. Loew, Dean
Tufts University School of Veterinary Medicine
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Dean Loew opened the morning sessions by welcoming everyone to the seminar.
Following self-introductions by the participants, the Dean explained the history and
purpose of the Center for Animals and Public Policy and reviewed the scope of its
activities stressing that it was similar to a small "think tank" whose function is to
conduct scholarly examinations and analyses of contemporary animal issues being
debated by the general public by reviewing the existing literature, exploring the
intellectual underpinnings, conducting independent research projects and reporting
the results. He pointed out that the Center is unique in the U.S.
He then explained the role of The Pew Charitable Trusts who, for two and a half
years, have generously suppo:..·ted Center projects.
Dean Loew noted that one turning point in regard to concern about the use of
animals in research occurred with the publication of an article in Science in 1976 by
Nicholas Wade. This represented the first time that a major science publication
gave serious consideration to the arguments of the animal protection movement.
After briefly reviewing the April meeting on animals in education, the Dean
explained the philosophy behind the seminar format design and the process for
selecting participants. The goal was to develop an academic debate on arguments
against animal research and testing. He stressed that even though many of those
present were in the "advocacy business" and critical of animal research, all had been
identified as intellectual leaders in this field and were capable of dealing with the
ideas being presented in a constructive manner.
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ANALYSIS OF THE ARGUMENTS AGAINST ANIMAL RESEARCH
Andrew N. Rowan, Director
Center for Animals and Public Policy
Tufts University School of Veterinary Medicine

(Dr. Rowan's talk was based on the following text which was included in the
preconference readings.)
Introduction

I
I

The use of animals in experimentation has a long history which, for the past few
hundred years, has included a passionate debate over whether or not animal
experimentation is moral. Despite the claimed productivity of animal research and
our modern ability to take more or less effective steps to cure or ameliorate many
diseases, the debate about the use of laboratory animals is today more heated than
ever (Phillips and Sechzer, 1989). Opponents still challenge the morality and
practice of animal research through the usual mechanisms of civic protest, and a
small group of activists are even prepared to risk arrest and imprisonment by
engaging in acts of theft and vandalism to publicize their beliefs and arguments.
Why has society been unable to develop appropriate mechanisms to defuse the
passion and the polarization of this debate? Part of the problem has always been the
emotive loading given to particular terms. Thus, opponents will talk of torturing
animals in laboratories (implying some level of sadistic motivation among
scientists) and scientists will refer to animal activists in similarly unflattering terms.
Both sides also tend to take refuge in relatively absolute positions when they are
confronted by the media, or under threat, or seeking public support. It is not easy to
develop a reasonable dialogue that leads to practical policy solutions under such
circumstances.
In addition to the unflattering attitude of each side for the other, there is no shortage

of people on both sides who hold strong ethical positions. Views such as, "... it is
meaningless to speak of their [animals'] rights to existence because they would not
exist if man did not exist" (Jacobs, 1984, p. 1344-1345) and, "Whatever gains we might
have harvested, for present or future generations of human beings, would have
been ill-gotten" (Regan, 1989, p.28) are fairly common. Such views are also more
likely to be publicized by the media because stark opposition is perceived to make for
a better story in the age of the ten-second sound bite than subtle arguments and
nuanced differences.
The current unproductive rhetoric over animal research comes at a time when it
should be easier than ever to construct a reasoned dialogue around which to build a
public policy consensus. According to most accounts, biomedical research
(including research on a.nimals) has produced tremendous advances in knowledge,
3

life expectancy and health care (but see McKeown, 1979, for a challenge to this view).
At the same time, the biological sciences have made remarkable technological
advances that have led to a relatively dramatic drop in laboratory animal use (3050% over the past ten to twenty years) and a greater ability to promote laboratory
animal well-being and alleviate animal distress than ever before. By contrast, at the
end of the nineteenth century, when the animal research debate was almost as
impassioned as it is today, very few therapeutic advances could be demonstrated to
have emerged solely and specifically from animal research, and animal care in the
laboratory was very crude by today's standards.
One problem in trying to address the policy issues is the lack of any detailed
examination of the various arguments together with an assessment of their validity
by a relatively independent group. The Tufts Center for Animals and Public Policy
is currently engaged in such an exercise and in this paper, focuses on one subset of
the arguments opposing the use of animals in research--the technical/ scientific
arguments.
In the last twenty years, the animal protection movement has recruited many

professionals into its ranks, and they have produced a variety of different moral and
technical challenges to animal research. There has been some attention to the
moral arguments and their shortcomings and implications by relatively
independent groups (e.g. Donnelly and Nolan, 1990; Smith and Boyd, 1991) but the
technical arguments have tended to be ignored because the research establishment
either did not wish to "give credibility" to the opposition or because the arguments
are perceived to be so ill-founded as to be worth no response. Nevertheless, these
new technical arguments have sometimes garnered considerable respect from both
movement members and the public, and it seems inappropriate that a community
of scholars should deal with contrary or disagreeable arguments with little more
than silence.
One of the first critiques was by Verhetsel (1986) who took on both moral and
technical arguments against animal research. But his self-published monograph has
largely been ignored. Charles Nicoll, a U.C. Berkeley scientist, has also critiqued
some of the material and has a paper in press that criticizes Singer's chapter in
Animal Liberation on animal research. The most detailed and compelling critiques
are, however, those by Paton (1993) and Botting (1992 and 1993). We propose to
extend their challenge in this paper. We start by categorizing these technical
challenges to the animal research approach and then analyze two specific cases, the
discovery of insulin and the development of the polio vaccine. Both of these have
long been regarded as triumphs of animal research but these views have been
strongly challenged by critics of animal research (e.g. Reines, undated; Sharpe, 1993).
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Criticisms of Animal Research: An Overview
The various technical criticisms of animal research may be classified into the
following two broad themes: first, the practice is unnecessary, and, second, the
practice produces too little benefit to balance the harm done to the animals .
A. Animal research is unnecessary
Some critics of animal research argue that animal research is not necessary
because:
1)
better use of preventive medicine will eliminate the need for animal
research;
2)
greater use of and reliance on public health measures will eliminate
the need for animal research;
3)
clinical approaches provide all the clues we need while animal
research merely dramatizes clinical discoveries; and
4)
the development of alternatives eliminates the need to use animals.
1. and 2. Prevention and public health

Opponents of animal experimentation propose that the prevention of disease is the
only truly effective way to insure universally good health. Sharpe (1988, p.49) states
that since, "... treatment has little impact and often comes too late, real
improvements can only come by preventing the disease in the first place." But a
healthful diet, regular exercise, and avoidance of harmful substances is not always
sufficient to keep people free of disease nor even alive in the modern world. Risk
of injury and disease cannot be eliminated and life involves making constant
compromises between conflicting risks.
The first two arguments tend to overlap and are vulnerable to the same general
rebuttal--namely, that both preventive medicine and public health initiatives are
heavily influenced by the development of new knowledge, a considerable amount
of which is generated via the use of animals. Thus, it is true that the incidence of
many of the major diseases was declining steadily before the advent of antibiotics,
vaccines and other drugs (McKeown, 1979), but the development of clean water
supplies, better hygiene, improved food supply and other measures that have been
identified as contributing to the decline· in infectious disease mortality occurred as
the germ theory was being confirmed (including the adherence to Koch's postulates
that required animal experimentation), as our knowledge of pathogenic organisms
exploded and as other advances in biomedical knowledge were being made. It
would be very surprising if one could isolate such advances from changing societal
attitudes about hygiene and disease .
The history of medicine is full of examples of clever detective stories suggesting
potentially important therapies that were not aggressively applied (or were even
ignored or suppressed--e.g. the story of Semmelweiss and puerperal sepsis) until the
5
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mechanism of the disease was more thoroughly understood. The connection
between lung cancer and cigarettes is a more recent story of the linked role of
epidemiology, pathology and laboratory research in supporting (all too little and too
late) appropriate public health measures. (It is also an example of how powerful
interests can manipulate the research enterprise to their own advantage.) One can
legitimately argue that the animal and other laboratory research should not have
been necessary, but, in the real world, the animal studies (and clinical
investigations) played both a positive and negative role.
Even though diseases such as tuberculosis were in steady decline through the
nineteenth and first half of the twentieth century, there is no question that the
therapies developed, as a result of animal research, to treat sufferers were effective
and important to those individuals who took advantage of them. When isoniazid
and streptomycin became available to treat TB, there were still 50,000 people in the
United Kingdom with the disease. As Paton (1993) shows, these two drugs produced
a marked improvement of the outcomes of those with TB.
Also, the charts and statistics that are usually cited to support the idea that public
health measures could have replaced much animal research are based on mortality
figures rather than measures of morbidity and suffering (although McKeown, 1979,
does begin to address this issue). If a family member came down with pneumonia
prior to 1935, symptomatic treatment was all that was available. Many individuals
survived their bout with pneumonia but they, and their loved ones, suffered
through one to two weeks of uncertainty, high fever and considerable distress. The
survivors then had lengthy weeks or months of recuperation ahead. After the
sulphonamides and other antibiotics were discovered (involving a number of key
studies on animals), pneumonia became a relatively minor inconvenience for most
people. The sense of control over disease that modern advances in health care have
provided may be very important in improving quality of life measures.
Thus, one can make some important arguments about the importance of
prevention and public health initiatives in human health and even grant the
argument that modern medical research has contributed only a small part directly to
extending life expectancy. But one cannot imply either that these measures were
not influenced by knowledge derived from animal research nor that prevention and
public health by themselves are responsible for the considerable ability we now have
to control morbidity and suffering.
3. Clinical studies
The third claim in this category implies that animal research is unnecessary because
we can achieve the same or better results by relying on clinical research. In the
United States, a considerable proportion of federal biomedical research funding
(around forty percent) does support clinical research while approximately one third
supports animal research. Thus, the call to support clinical studies is already being
met to some extent. The question is whether the clinic can completely supplant all
6
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animal studies. Brandon Reines, a veterinarian who now concentrates on medical
history, has argued this issue most forceful~y, drawing .on~ ~ariety of ca~ studie.s,
including the discovery of some psychoact1ve drugs v1a chrucal observation (Remes,
1990) and other case studies. In addition, Kaufman et al (1989) have produced a
critique of animal models which argues that animal models are rare.ly. cited in. t~e
clinical literature and are, therefore, not useful in terms of actual chrucal med1cme.
The case studies cited by Reines draw on instances where astute clinicians (following
William Osler's advice) use interesting cases and clues from the clinic to make
conceptual or therapeutic leaps into ~ew areas. .For exam:ple, i~portant .
psychoactive drugs (e.g. chlorpromazme) were dlSco:v~red m this way <RE:mes, 1990).
However, this naturally led to a whole range of add1t1onal research quest1ons a~ut
the mode of action of such drugs and the possibility of developing other drugs w1th
different (improved?) properties. Thus, the initial observation or intr~guing clue,
whether clinical or experimental, is only part of the process of developmg new
knowledge and new therapies.*
In the critique of animal models, Kaufman et al (1989) analyze citations to ten .
randomly-chosen models from the animal model files at the Armed Forces Institute
of Pathology. Of 693 citations to the 21 core papers describing the animal models, 78
(11.3%) were clinical with most of these citations (61) referring to only three of the
models. The authors note that many of these citations appeared to be clinically.
unimportant and they conclude by questioning the usefulness of these models m
understanding and treating human disease.
This study represented an interesting (and to this date the most sophisticated)
attempt to undertake an objective analysis of the utility of animal mod~ls.
However, it is not without problems. Citation analysis has developed mto a
complex science with many potential pitfalls. For example, it is well known that
older papers rapidly disappear from the literature and become subsumed by more
recent reviews. Thus, their simple citation analysis tracked the influence of the
primordial papers that first described the animal model but not the influence of the
model itself. In addition, errors in citation are fairly frequent, and one has to be
careful to examine potential variants. Such variants can account for a significant
proportion of the total citation record.

. •f

There are other problems aside from the technical difficulties of citation analysis. It
is not clear how clinical "value" was judged nor how the citing literature was
divided into clinical papers and other types of research. The scientific literature is
also notoriously neutral in assigning value to prior literature, and it is likely to be
very difficult to determine how much impact an earlier paper has had on an
investigator merely by reading the journal report.
..It should be noted that Reines uses the term "discovery" in a non-colloquial way .. ~s far as I ca_n tell, "disco~ry" for
Reines is the moment of insight or question formation which often comes from a cltmail ob~rvatzon. The testzng_ of the
insight or question then is moved into a second phase of activzty by Reines which he somettmes appears to describe by the
term" dramatization."

7

The study also does not provide any control comparison, such as a citation analysis
of the clinical studies of the same human diseases which the animals were supposed
to be modeling. It may be that the clinical studies were similarly unimpressive in
influencing the later literature.
Finally, this analysis sets out to assess the idea of the usefulness of animal models.
However, much animal research only uses the animal as a model in the sense that
the research animal is a mammal, as are humans. For example, in toxicity studies,
mice and rats are used because they are small, relatively prolific mammals for which
a great deal of background information is available.
4. Alternatives
The best available statistics indicate that the use of laboratory animals worldwide
has fallen by 30-50% after peaking between 1975 and 1980. Several reasons have
been put forward to explain this decline. First, it is argued that laboratory animals
and their care have become increasingly expensive leading to an economic
disincentive to use research animals. This is true but there is no data showing that
animal research costs have risen any faster than general research costs. Second, it
has been suggested that animal use has fallen because of economic uncertainty and
recessions. During the last fifteen years there have been two recessions and one
boom period but animal use fell steadily throughout. In addition, RoffmanLaRoche reported that it cut its animal use from 1 million to around 300,000 per
annum over ten years while maintaining the same number of Investigational New
Drugs under study.
Third, it is argued that alternatives have played a major role. This is most likely
true but it is not clear how much of the fall has been due to the specific search for
and use of alternatives and how much has been due to the development of more
efficient and powerful research techniques that also happen to reduce animal use.
Thus, cell culture technology has improved considerably in the last fifteen years as
has our knowledge of basic biological mechanisms. Partly as a result, the National
Cancer Institute has replaced its use of the mouse cancer model for screening for
new chemotherapeutic agents with cultures of human cancer cells at a savings of
around 3-4 million mice per annum (Rowan, 1989). The pharmaceutical industry
has also made very good use of new techniques to reduce animal use in screening
for potential new drugs.
Even given the progress made in reducing animal use (and in reducing animal
distress in research) over the past fifteen years, it is difficult to see how animals
could be eliminated now or in the foreseeable future from many research areas. By
combining clinical, public health, cell culture and other approaches to research, it
may well be possible to reduce animal use still further (perhaps substantially), but it
is not realistic to expect to eliminate all animal use in the laboratories of the OECD
countries and also argue that biological and medical research would be unaffected.

8
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Finally, as indicated by the two papers on Nobel Prize Winners who used
.
alternatives (Stephens, 1986) or animal models (Leader and Stru:k, 19~7), there. Is
room for disagreement on the role played by. alterna~ives ?r animals m a particular
discovery. A substantial proportion of the winners hsted m the two papers are the
same.
B. Animal research causes too much suffering for little/no benefit
Another argument used to criticize animal research addresses its utility for
humankind. Some suggest that animal research produces a tremendous amo~t of
suffering and little human benefit. For example, Singer (1990) states that he thinks
that much animal research "... is of minimal or zero value" w~ile it causes. .
considerable suffering. Others suggest that no animal research .Is useful ~~ile It
causes considerable harm to animals. For example, the Australian Assoaation for
Humane Research (1988, p.1) states, "We know of no animal experiments, as such,
which ever led to a cure of a human disease."
Finally others argue that animal experiments are not only useless, but are actually
misleading. Sharpe (1988, p.200) states that, "... the real choice is not between dogs
and children, it is between good science and bad science; between me~ods ~hat.
directly relate to humans and those that do not. B~ ~t~ very n~t.ure viviseetlOn IS bad
science: it tells us about animals, usually under artificial conditlOns, and ~ot about
people." All three approaches are found, sometimes tog~ther and ~ometlmes not,
but all depend on refuting the research argument that arumal studies have proved
to be very useful at a relatively small cost in animal suffering.
How much suffering is caused by animal research?
We have relatively little data on animal suffering in resear~h and test~ng and what
we do have depends heavily on what is perceived to constitute ~uffenng. ~hus, .no
establishment assessments consider that rats or mice suffer particularly while bemg
housed in a research facility, or at least not when compared to a similar life in .
nature. The appropriateness of housing conditions for the larger laboratory arumals
have recently come under much greater scrutiny and animal care. standards for
them are changing quite rapidly. However, critics appear ~o consider .eve~ the new
standards grossly inadequate. Interest in carnivore and pnmate housmg IS now.
spilling over to the other species and the housing s~andards for rodents and rabbits
are also being examined and improvements are bemg suggested. Noneth.eless, the
available assessments of animal pain and distress in research do not consider the
effect of care and housing practices.
The authorities in The Netherlands have collected data on the potential pain and
suffering experienced by laboratory animals under sn:dy. The 1~90 Ann~al Report
on animal experimentation notes that 53% of the arumals expenence mmor .
discomfort, 23% were likely to experience moderate discomfort and 24% were hkely
to experience severe discomfort. About one fifth of the animals in this last category
9

were given medication to alleviate pain. Examples of procedures that would place
animals in the "severe" category are prolonged deprivation, some experimental
in~ections, tumor induction, LD50 testing, and immunization in the foot pad or
With complete Freund's adjuvant (The Alternatives Report, 1992). All of the
animals are likely to be euthanized so they will also experience the harm of death.
In Great Br~tain, the only indication of pain control that is available is the recording

of anesthesia use. In 1978, 3% of the 5.2 million procedures involved anesthesia for
the whole procedure (they were terminal) and 14% involved anesthesia for only
part of the procedure. In 1988, 19% of the 3.5 million procedures involved
anesthesia for the whole procedure and 17% involved anesthesia for only part of the
procedure. It is not clear why anesthesia use doubled from 1978 to 1988 although
the 1986 Act that revised British controls over animal experimentation placed
greater e~phasis on the control of pain and distress (The Alternatives Report, 1990).
However, It would appear that potential pain was being underassessed prior to 1986.
According to 1992 USDA statistics, 5.63% of the animals used in research in the USA
experience pain or distress that is not alleviated by painkillers. However, USDA
statistics on pain and distress are regarded with some suspicion by critics of animal
research (and rightly so), especially in light of the tremendous variation in the way
different institutions report their use of animals by pain category. There is also
some direct evidence that actual use of post-operative pain relief is lower than stated
(Phillips, 1993). States vary dramatically in the proportion of research that is
reported to be painful and for which pain-relief is not provided. Kansas (45.5%),
W~shington (30.~%) and Colorado (26.0%) reported that more than a quarter of their
arumal research mvolved unrelieved pain while some relatively big users like
Arkansas (0.03%), Delaware (0.65%), Florida(0.70%), Maryland(0.82%),
M~ssachusetts(0.98%), Nebraska(0.13%) and Texas (0.70%) reported less than 1% of
animal research in the unrelieved pain category. The USDA statistics cannot be
used as a reliable assessment of research animal pain and distress.

De~pi~~ the problems of assessing animal pain and distress and the questionable
reliability of some of the numbers, the available evidence does not indicate that all
or even a majority of research animals experience severe and unrelieved suffering.
Of course, how one judges the total extent of animal suffering (and whether it is
excessive) is going to be heavily influenced by one's personal values and
interpretation of the data, and by one's assessment of the level of harm caused by
the killing of animals.
I

What are the benefits of animal research?
Having attempted to address the cost side of the equation, what of the benefits?
These are no easier to judge. Nonetheless, our knowledge of the natural world and
hum~ biology h~s expanded .enormously in this century (although one may
question changes m human w1sdom over the same period). Our ability to develop
vaccines, antibiotics, public health initiatives and reasonably good nutritional
10
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advice is much greater than it was even forty years ago. About forty percent of the
research that has produced this knowledge used animals (at least according to NIH
analyses of its funding allocations) and it seems reasonable to assume that, whatever
value we place on our current store of knowledge, then 40% of the credi~ should go
to studies using animals. However, it is not really possible to separate d1f~erent .
research approaches to apportion credit. Research tends to be ~n. endless orcle Wit~
insights flowing from the clinic to the laboratory to the theoretloans ~d back agam.
If the flow is disrupted, then one will lose much more than the portion removed.
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It is difficult to discuss these issues in the abstract which is why so many of the
criticisms and defenses of animal research tell narratives about particular incidents
or discoveries. Two case studies have been selected for more detailed discussion
here--the discovery and development of insulin, and the development of the p~l~o
vaccine. Both have been put forward as examples of triumphs of modern med1one
and have subsequently been criticized in animal protection literature. They thus
serve as interesting examples of the claims and counter-claims in the animal
research debate.

A. The c'lscovery of insulin
The discovery of insulin as a treatment for diabetes mellitus has been described as
"... one of the genuine miracles of modern medicine" (Bliss, 1982, p.ll) and the role
of animal experimentation in this discovery has received attention from both sides
of the debate. A critic, Brandon Reines, claims,"... the animal experiments
provided no dear direction, though ultimately the illusion was created that ani~al
experimentation had led to the discovery of insulin" (Reines, undated, p.11) while
Charles Best, co-discoverer of insulin, claims his work to be "... only one of the
many, many thousand series of experiments which testify to the importance o~ dogs
in medical research." (Best, 1974, p.439) Examining the arguments for and agrunst
animal research in the discovery of insulin should help us to judge their coherence
and may help us assess what value we might place on at least some animal
experimentation.
Diabetes is a disease which contradicts the claim that a high standard of living is all
that is needed to remain healthy (assuming a well-fed state is one component of
good health). "There tended to be more diabetics among people who ~ere.
prosperous and well-nourished rather than among the poor and lean. (Bhss, 1982,
p. 21) It is also a disease which contradicts Sharpe's claim that" ... most disease is
self-limiting ... " (Sharpe, 1988, p.32) and the juvenile form of the disease cannot yet
be prevented although it has been suggested that its incidence might be reduced by
appropriate public health initiatives .
However, the case of diabetes does address the impact of new research knowledge on
morbidity and distress (rather than the more absolute measure of mortality which
hides many changes in human suffering since life is associated with inevitable
11
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decline and eventually death). The question of morbidity has been raised by critics.
For example, Sharpe challenges the research paradigm with the statement,"... if
vivisection were making such an enormous contribution we could confidently
expect a massive improvement in health." (Sharpe, 1988, p.15) Did diabetics
experience an improvement in health due to the discovery of insulin and was that
discovery a triumph of animal experimentation?
Elizabeth Hughes's life is an excellent example of the life of a diabetic before the
discovery of insulin. Elizabeth was diagnosed as diabetic in 1919 at the age of eleven
or twelve and, in those days,"... the diagnosis was like knowing a sentence of death
had been passed." (Bliss, 1982, p.43) The only available treatment at that time was a
starvation diet developed by Frederick Allen. Dr. Allen developed this treatment
after experiments on dogs which had been rendered mildly diabetic by partial
pancreatectomy (thus mimicking human diabetes more closely than complete
pancreatectomy). He discovered that undernourishment allowed the diabetic dogs
to live symptom free. However, this form of treatment was never easy on the
diabetic and required a diet that most patients could not sustain, either physically or
mentally. The usual outcome was death by starvation if the patient did not break
diet and die of diabetic acidosis. Doctors who worked on the diabetic wards before
1920 were reminded of those wards when pictures of the Nazi concentration camp
victims_ appeared after the Second World War.
Elizabeth Hughes's experience on this diet exemplifies the problems with this
treatment and the suffering and discipline required of the patient.
Had she been untreated, Elizabeth Hughes would probably have died in the
summer of 1919. With Dr. Allen's stern diet, her own discipline, and her
sheer strength of character, she carried on very well through the winter of
1919-20. She had a difficult time in the spring of 1920, when colds and
tonsillitis threw her out of balance, and was often cut back to a diet of less
than 500 calories. But she recovered that summer and fall, and at Christmas
1920 weighed in at 621/4 pounds. The winter and spring were bad again,
though; by the end of March she was down to 52 pounds. Her diet in April
averaged 405 calories. The doctor got her back up to 700 to 900 calories, but
her weight was now at a new low plateau, between 52 and 54 pounds. At the
age of thirteen, Elizabeth was a semi-invalid. (Bliss, 1982, p.44)
However, she did not die in 1922. Her father had the means to purchase the best
medical care and she became one of the first people to receive insulin in Toronto.
When she arrived; she was 5 foot tall and weighed 45lbs but the insulin extracts
rapidly cleared the sugar from her blood and within two weeks her diet had been
increased from 890 calories to 2,400. Elizabeth Hughes could not believe her good
fortune and wrote to her mother, "It is simply too wonderful for words this stuff"
(Bliss, 1982, p.152). In 1929, Elizabeth Hughes graduated from Barnard College and
married a young lawyer. She had three children and became prominent in civic
affairs in the Detroit area where her husband worked for Ford Motor Company.
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She died in 1981 from a heart attack after 43,000 insulin injections and a full life
rescued from the "nightmare" years of starvation before insulin.
Elizabeth Hughes is a single person but there have ~een countless ?t~ers sin~e then.
It is difficult to dispute the value of insulin therapy m the .face of surular s.ton~ of
the alleviation of such suffering to produce decades of active and productive hves.
However, McKeown (1979) argues that the majority of diabetics .<who experience the
adult onset form of the disease) do not experience the type of muaculous change
seen in the smaller group of juvenile diabetics. Nonetheless, insulin therapy ~as
had a significant impact on patients and it now remains to assess what role arumals
played in the discovery. There are several potentially key discoveries and much
spinning of wheels in the insulin story.
Early on diabetes was diagnosed by the sweet taste of the diabetics urine but
knowledge about the etiology of the disease was scant. Reines (undated, p. 9) then
suggests that the first link between d.iabetes and the. pancreas ~as demonstrated by
Thomas Crawley in 1788 whe::1 he d1scovered multipl~ calcuh .m t~e pano:eas of a
patient who had died of diabetes. Other autopsy stud1es on d1abet1cs ~onfirmed
Crawley's observation and suggested that the pancreas was the most hkely. org~
affected in this disease. Then, in 1869, Langerhans found two cell populations m the
pancreas, one of which secreted the digestive juices b~t he .did not know what the
other cells did (these were the beta cells that secreted 1nsulm).
According to Bliss (1982, p.25) (and contra Reines), evidence connecting the pancreas
and diabetes was still tenuous in 1889 when Oskar Minkowski and Joseph von
Mering made their discovery. They had removed the pa~creas from a. dog to ~ee if
the pancreatic digestive enzymes were vital to the digestion of fat. Mm~owsk1
noticed that the dog was urinating on the laboratory floor even tho~gh 1t w~s
house-trained and tested the urine for sugar (he had been told by h1s supervisor to
test for sugar whenever he saw polyuria). He discovered that the dog had become
diabetic. This led the way for other researchers such as Hedon ~ho, in 1893, !:'roved
in further experiments on dogs that the pancreas produced an mternal secr~t10n
into the blood stream which controlled the metabolism of carbohydrates (Bhss,
1982).
This discovery unleashed a flurry of research aimed at producing a pancrea~ic extract
that could be used to treat diabetes. This approach grew out of other work m the
1890s that had showed that several diseases (e.g. goiter and cretinism) could be
treated by extracts of the thyroid. In the first few years of the twentieth century, the
new field of endocrinology was blossoming and many investigators were searching
for the pancreatic extract. However, the initial studies produced confl~cting results
and many red herrings and experienced researchers learned to be cautlous of
"pancreatic extract" effects. With the hindsight of history, Bliss (1982) identifies
several researchers who might have been on the right track, but it is clear that the
evidence did not point clearly in any one direction when Banting approached
MacLeod in Toronto to do his dog experiments.
13

IIIII
Reines (undated, p.3) argues that" ... it is clear from the factual evidence presented
in Bliss' book that the animal experimentation which preceded the discovery of
insulin was not part of the scientific process that led to the discovery of insulin" arid
he and others credit a clinical observation for stimulating his dog research.
According to a booklet produced by the Australian Association for Humane
Research (1988, p.7), "... the real breakthrough came through the clinical work of an
American pathologist, Dr. Moses Barron" who published a paper on a patient with
a rare case of pancreatic lithiasis in which the stone blocked the main pancreatic
duct. He reported that, while the acinar cells- had atrophied, the islet cells appeared
to be intact. This gave Banting the idea that he could obtain healthy islet cells from
which to prepare pancreatic extract by ligating the pancreatic duct and waiting for the
acinar cells (that were proposed to contain a substance that destroyed the 'active
principle' in the pancreas) to atrophy.
One breakthrough in diabetes research that occurred prior to the Toronto team's
success, and certainly is part of what made their work successful, was the
development of an easy and accurate way to measure sugar in the blood. Bliss (1982,
p.40) states, "The single most important development in diabetes research, next to
Allen's diets, was the rapid improvement between about 1910 and 1920 in
techniques for measuring blood sugar." This development was so important
because it permitted the measurement of blood sugar directly rather than the less
accurate measure of a reduction of sugar in urine.
Another important ramification of the development of a better technique to
measure blood sugar was that it quite possibly influenced Macleod's decision to
encourage and assist Dr. Banting with his experimental ideas. Macleod certainly
knew that other researchers had failed to isolate a useful pancreatic extract to treat
diabetes, but also must have known that" ... almost all experiments done in the
past, with pancreatic extracts or by any other method, might show different results
now that blood sugar could be tested easily and quickly" (Bliss, 1982, p.53). So, when
Banting approached Macleod with his idea of how to isolate an anti-diabetic
substance from the pancreas, Macleod agreed that the experiment was worth trying
and agreed to provide Banting with laboratory space, some dogs, an assistant, and
guidance.
Banting and Best's research on dogs during the summer of 1921 is well known but
Bliss (1982) uses material from the original data books to point out the numerous
errors in their research and their reporting of it. However, the results were
sufficiently encouraging for MacLeod to call on the services of Collip, a biochemist,
who started working to purify the pancreatic extracts. One of Collip's key
contributions at this stage was to demonstrate that the potency of the pancreatic
extract could be readily tested by measuring its blood-sugar-lowering ability in
normal rabbits. He was later responsible for describing the hypoglycemic shock
reaction (and associated convulsions) and for showing that it could be reversed by
the administration of glucose in his rabbit studies. When it came time to prepare
insulin extracts from farm animal pancreases on a commercial basis, an animal
14
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convulsion test became a critical part of ensuring that batches of relatively uniform
potency were distributed.
One can question the role of th~ dog studies done by Bantin~ and Best ~nd. it is clear
from Bliss's (1982) analysis that insulin would have been d1scovered Wlthin a year
or two even if Banting had not been given space by MacLeod because of ~uch
technical developments as a better test for blood sugar. Nonetheless, ~mals~
notably the rabbits used by Collip, played a critical role in the successf~ 1solation of
insulin. Reines's argument that animal research had not led to the d1scovery of
insulin while also claiming that Banting and Best's (invalid) hypothesis stem~ed
from a clinical observation published by Barron is, to the say the least, paradoXlcal.
H the animal research was unimportant, then the clinical observation that led
Banting to his studies must also have been unimportant.
Ultimately, what the insulin discovery story demonstrates all too clearly is the
difficulty of biomedical research, the sloppiness of some of the work, the frequent
blind alleys followed by both clinical and experimental investigators, ~nd the
mixture of chance, technique availability, clinical observation and an1mal
experimentation that all play a role in advancing knowledge.
B. The polio vaccine story
The history of the discovery of the polio vaccine shares ~any features with. the
discovery of insulin. Like the discovery of insulin, the d1scovery of the poho .
vaccine has been described in grand terms such as" ... one of the greatest techn1cal
and humanistic triumphs of the age" (Paul, 1971, preface). Like diabetes, polio had
no satisfactory treatment, could be fatal, and children were amo~g th~se a~fected .
(polio primarily affected children). In addition, polio appeared m ep1dem1c form m
countries with high standards of hygiene and did not appear to be preventable by
leading a healthful life.
Early attitudes toward polio were dominated by a feeling of hopelessness. As the
disease grew into a national problem, parental concerns grew and mothers would
keep their children away from communal places in the summer because of fear of
the disease. It has also been suggested that some "epidemics" might h~ve been
caused by mass hysteria, exacerbated by such treatment patterns as put~ng c~sts on
any limb that appeared to show signs of weakness, rather than actual mfect10n (Paul,
1971, p. 224). When the vaccine for polio virus was finally developed, t~e ~uccess
was due to the efforts of many researchers over a long period of tlme bullding on
knowledge gained through experiments involving animal and non:a_n~mal
methods. The animal experiments have also become the focus
cntlasm fr~m
animal activists, probably because polio is often presented as a tnumph of an1mal
research .

o!

The major criticism that appears to be leveled at animal research on polio is.
encapsulated in the stat'i!ment that, "Tragically, animal experiments so dommated
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prior to 1937 most scientists rejected the notion that polio is an
mtes,tinal d1sease". (Sh~pe~ 1993). This claim is usually bolstered by reference to
Pauls (1971) mag1stenal h1story of the polio story that describes the wrong direction
taken by Flexner at the Rockefeller Institute as a result of his reliance on monkey
data. However, as Paul also documents, there were many other missteps in the
~arch. for a therapy for polio, many of which were advanced by clinical
mvestlgators.
Poli~ is unlike diabetes in that it occurred in epidemics that developed out of a
pr~v10u.s endemic condition. The transition of the disease from endemic to
ep~dem1c occurre~ ~th, and was due to, the development of modern sanitation.

W1~ mo~ern. san1tat1on,. children. were
~he 1nf~ction 1s usually sllent. W1thout

not exposed to polio virus in infancy when
early exposure children were not naturally
~mmunized against polio virus, and therefore large numbers of them could be
m~ected at one tim:, leading to the appearance of the epidemics. In addition, older
children are more hkely t~ suffer the associated paralysis (Marten, 1981). Therefore,
one cannot argue that pol10 would have been prevented by better public health
measures.
~ith ~he

advan.cement of sc~entific knowledge about the nature of contagion and
infect1on, the etiology of poho slowly began to be puzzled out. With such
knowledge came a growing hope that there could be a way to prevent or treat this
d~eaded an? a~~arently spreading disease (Paul, 1971). Knowledge from many
d1ffer~nt sc1e?t1f1c approaches, including epidemiology, clinical studies, animal
expenmentat1on and in vitro studies came together to build the knowledge base
that allowed the development of the polio vaccine.
B?th Pasteur's and Koch's theories of contagion and infection, and the birth of
~stology, were. important steps in the path to a polio vaccine. Before the advent of
histology, the s1te of .the lesion of polio virus was not agreed upon, and so polio (a
name based on.the s1te of the lesion) was usually known as Infantile Paralysis. In
1870 Charcot d1scovere~, thro~gh examinations of autopsy specimens (clinical
work), that the ~natormc location of t~e lesion was in the anterior horri of the gray
matte.r of. the spmal co~d, rather than m the muscle or peripheral nerves. Later
e~armnatio?s of the spmal cords of monkeys sacrificed at different stages of the
d1s~ase (arumal research, and studies that could not be done with human polio
patlents) helped elucidate the degenerative nature of the lesion.
pa~ologic organism of polio was also not agreed upon until 1908 when
Lands~eme~ and Popper infected two primates with polio by injecting them with
bactenolog1~ally sterile spin~l cord s~ple~ from a fatal human case of polio (Paul,
1971?. The ~mportance of this expenment m leading to an understanding of polio,
and m help1~g explain why the monkey model was chosen time after time by

The

researchers, 1s expressed by Paul (1971, p.100):
Seldom has the record spoken louder or in a more convincing
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manner than it did when one of these monkeys "came down" with
paralysis, and louder still when they were shown to have lesions
within the spinal cord exactly like those seen in human poliomyelitis.
The monkey model convinced even skeptics that polio was caused by a virus.
Subsequent to Charcot's 1870 discovery of the site of the spinal cord lesion, Rissles,
in 1888, pointed out the extra neural lesions of acute polio. His findings led him to
the correct conclusion that polio is actually a systemic disease rather than
exclusively neurologic. Many years later, in 1912, a team headed by Carl Kling in
Stockholm, isolated polio virus (by infecting monkeys) from the throat and small
intestine of both fatal and acutely ill polio victims. These findings indicated how
polio virus might enter and exit the body, and therefore how it is transmitted. One
member of Kling's team correctly concluded from epidemiological studies that
immunity to polio could be naturally acquired ·through the process of sub-clinical
infection. However, these data were soon forgotten or ignored as new studies
(including both animal and clinical investigations) painted a different view of polio
(Paul, 1971).
Paul (1971, p. 108) notes that Flexner was so impressed by how closely the primate
neurological lesions resembled those in humans that he decided that one could
study the disease in either monkeys or humans and he chose monkeys.
Unfortunately, his studies on monkeys led him to determine that polio was a
neurogenic infection and his stature in the field caused many to follow this idea.
This led people away from the fact that polio might be a systemic infection but
claims that this false step retarded the development of the vaccine can be disputed.
The technological advances in tissue culture that permitted the production of large
quantities of virus occurred during and immediately after the war and not from
1910 to 1937 when Flexner's ideas held sway.
However, Flexner was not the only person to pursue false leads. A number of
strange theories were proposed. One such was George Draper's 1917 theory of
"constitutional susceptibility, " which he formulated through his clinical
investigations of children with polio. He concluded that "... large well-nourished
children with widely spaced teeth ... "(Paul, 1971, p. 162) were more susceptible to
polio than other children. While this conclusion may now appear ridiculous, it was
widely supported for the next twenty years and it was even suggested that, had a
prophylactic measure been developed, it should be reserved for those children who
qualified as susceptible by Draper's standards (Paul, 1971). These examples, one from
clinical research and one from animal experimentation, demonstrate that neither
approach was immune from error.
In 1931, Burnet and Macnamara made the important discovery that there were
serologically different strains of the virus using monkeys (Paul, 1971). Their
findings later inspired the 1946 virus-typing project using large numbers of
monkeys that was very important in the development of a vaccine (Paul, 1971) .
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Monkeys were not the only animals used for polio research. In 1935, Maurice
Br.odie and his colleagues succeeded in adapting polio virus so that it could infect
rruce (Paul, 1971). In 1939 Charles Armstrong, and later Max Theiler, succeeded in
experime~tally infecting c~tto~ rats, and later mice, with the Lansing strain (Type II)
of the J;>Olio Vlru~. These fmdmgs were important because they facilitated an
expansion of poho research, due to the much reduced cost of experiments on mice
C_?mpared to monkeys. Another important insight from mouse studies was the
fu~~mg t~at the ~irulence of polio virus could be attenuated without losing its
~bihty to rmmuruze (Paul, 1971). This pointed the way to the development of the
hve-attenuated Sabin polio vaccine.
Another major contribution to polio research came in 1948 with the successful
growth of polio virus in cultures of human "non-nervous" tissue developed by
Enders, We~ler, a~d Robbins. !he availability of reliable cell culture technology
now made It possible to quantify the amount of virus in a tissue culture sample, and
to. r:pla.ce mo~ey use with tissue culture for many purposes. This technique was
cntlcal m leadmg to the production of a polio vaccine from non-nervous tissue (a
far safer alternative), containing an accurately measured amount of virus (Paul,
1971). The development of antibiotics to control bacterial overgrowth in tissue
cultur~ was a very important preliminary step leading up to the finding by Enders
and ~s colleagues. So, while the final Nobel Prize winning "discovery" in the polio
vacane story was an "alternative," its development involved innovations derived
from animal research.
The use of animals in polio research and production has declined dramatically since
hundreds of thousands of monkeys were used every year in the 1950s at the height
of the race to develop a vaccine. This decline can be attributed to improved
!echnology and the implementation of alternatives. For example, further technical
Imp~ove~ent~ led to dramatic reductions in the annual use of animals in polio
vaccme (mactivated) production in The Netherlands from 4 500 in 1965 to 30 in 1984
(Hendriksen, 1988, p. 59). The debate about animal use in ~urrent methods of
produc~on and testing of polio vaccine is described in great detail in other books
and articles on the subject of polio (see Hendriksen, 1988; LeCornu and Rowan, 1979;
Marten, 1~81; an~ Rowan, 1:'34). H~wever, the polio vaccine story is another
e~cellent lllustra:wn of the mterlockmg nature of different research approaches, the
tn~mphs and missteps, and the way improved technology and changes in societal
attitudes has led t~ dramatic reductio.n~ in animal use. Thus, the polio story can be
used to b~lster drums for both the utlhty of animal research and the future potential
of ~lternatives .. It cannot be used as a good example of research error induced by
reliance on arumal models unless one is willing to accept that clinical research and
other research approaches are equally susceptible to such errors.
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SCIENTIFIC PROBLEMS WITH ANIMAL MODELS
Stephen R. Kaufman
Medical Research Modernization Committee

(Dr. Kaufman provided the following text.)
Historian and philosopher of science Thomas Kuhn notes that every scientific age
has it "paradigms," theories nearly universally regarded as true that form the
framework for ongoing scientific investigations) Paradigms are rarely challenged
until overwhelming contradictory evidence forces their revision or rejection. A
currently dominant paradigm is that animal "models" are necessary for medical
progress.2-4 For most members of the current scientific establishment, the issue is
not whether animal models should be used but which models are most useful.
However, critics of animal models argue that they are inherently flawed5-7 and
point out the frequency with which animal models provide misleading
information.S-12
All species differ; animal-model conditions never exactly mimic human ones.
Animal models are only analogues of human conditions because they share certain
characteristics. Philosophers Hugh LaFollette and Niall Shanks observe that animal
models are used primarily for two functions--to predict human responses to stimuli
(such as infectious, traumatic, or toxic conditions and therapeutic drugs or devices)
and to offer new ways of conceptualizing human anatomy, physiology, or pathology.
Researchers who use animal models employ the following reasoning: a given
animal model resembles an analogous human condition in some of its features (say,
A, B, and C); therefore, it is reasonable to proceed as if an additional feature (D)
found in the animal model - for example, a physiological function or a drug
response- can be expected to be a feature of the human condition as well. As
LaFollete and Shanks point out, this assertion is logical only if featureD is causally
related to A, B, and C--in both the animal model and the human condition. That is,
A, B, and C must be causal factors of feature D. The following reasoning illustrates a
failure to recognize the importance of causal relationships:
Two dogs bark, love bones, and wag tails when their human companions
arrive home; because the two dogs are similar in these respects, they can also
be expected to be of the same breed. If we know the first dog's breed, we can
reliably predict the second's.
Breed, however, is not causally related to the three features that the two dogs are
already known to share. If we know a dog's breed and we also know that a second
dog has the same parents as the first, then we can reliably predict the second dog's
breed--even if the two dogs differ in many other respects, such as coat color or
temperament .
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LaFollette and Shanks distinguish between weak and strong models. Strong animal
models are identical to the analogous human features in all causally relevant
respects, and research using such models can be confidently applied to humans.
Although many animal research advocates assert that animal models faithfully
reproduce human conditions, LaFollette and Shanks argue that most animal
models are weak models of little direct applicability to humans. Although they do
not reject animal research's value, they do note that animal research advocates
frequently assert that animal models faithfully reproduce human conditions, even
though most animal researchers recognize that animal models tend to be weak
analogues with limited utility.5 LaFollette and Shanks maintain that animal
models, as actually used by researchers, may be helpful but are probably not
necessary for medical progress.
In public, animal research proponents often suggest that weak causal models are in
fact strong. For example, the Stanford Committee on Ethics states, "Cancer kills
humans and animals alike."13 At any but the most simplistic level, the comparison
immediately begins to break down. For example, in their causes malignancies that
are experimentally induced in nonhuman animal and malignancies that occur
spontaneously in humans differ significantly .14-16 Other important differences
include the greater virulence of most experimental cancer strains and differing
mechanisms of tumor growth and metastasis. Even nonhuman cancers that
apparently share many characteristics with human cancers make unreliable research
models, since human and nonhuman cancers inevitably differ in some relevant
causal factors. Viewed in this light, an animal model such as the mouse-leukemia
model is a poor means of attempting to identify potential anti-cancer drugs, and this
model has, in fact, proved grossly inadequate.17
Even if a disease's main causal factors were well understood--and were alike--in
both humans and other animals, animal models would still be undermined by
systemic differences between animal models and human conditions. Because of
evolutionary divergence, species show differences in virtually every aspect of organ
and tissue function. All organ subsystems interact, so every physiological difference
between a given "laboratory" animal species and the human species necessarily
affects every given factor. Consequently, all tissues of an animal model will tend to
react to an experimental ma11ipulation differently than a supposedly analogous
human condition. Animal models of human conditions tend to provide only the
most obvious and general information, such as that cancers kill; in order for them
to provide reliable and specific information, the model and the human condition
must have identical causal factors and have no significant systemic differences that
affect these causal factors. This is impossible, since there are always differences in
causal factors between the model and the human condition and because systemic
differences are an inevitable consequence of evolutionary divergence.
In theory, then, animal modeling is unreliable in predicting human responses to

stimuli; and it has proved so in practice. Animal tests of acute lethal toxicity18, eye
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irritancy19-21, skin irritancy22-24, teratogenesis (birth defects)25- 27, and .
carcinogenesis28,29 have generally provided inconsistent results and failed to
correspond to human expe~ience. R. ~eywood has. estimated that only about. 5-25%
of toxic effects found in an1mal expenments occur m humans. Of course, arumal
models can serve as strong models when researchers attempt to predict gross
toxicological effects, such as the ability of strong acids to burn the er.e's surface;
however, such effects could readily be predicted from the ~ost rud1me~tary.
knowledge of chemistry. Most animal tests are supposedly mtended to 1dentify
subtle effects, and they perform poorly in this regard.
Animal tests have also proved inadequate as a means of identifying potentially
useful drugs. U.S. law requires that drugs be found effective and safe in animal
testing before they are tested on humans. This law fails to reflect animal tests' poor
predictive value: Ronald Hansen found that only about 12% of drugs that passed
Phase I animal tests and entered human testing reached the market3 1; earlier,
Samuel Irwin had found that only 2.3% of drugs selected for clinical trial were
eventually marketed.32 Most new drugs are similar to existing drugs, and so their
clinical effect can be at least partially predicted based on structural analogy. Also,
modern biochemical methods can help characterize specific drug-receptor
..
interactions and these interactions can suggest specific drug effects. Therefore, 1t 1s
debatable ~hether animal tests help identify which drugs are most suitable. for
human clinical trials (the critical step in determining human safety and efficacy).
In addition to having failed to accurately predict drugs' efficacy and toxic side-effects,

animal tests have, no doubt, prompted researchers to abandon numerous drugs and
therapies that proved ineffective or toxic in nonhuman animals but would ~ave
benefited humans. It is impossible to determine how many valuable therap1es were
discarded on the basis of misleading animal studies.
Are animal models worthless, then? Although causal dissimilarities and systemic
differences undermine animal models, they are not necessarily useless. For
example, animal data need not accord perfectly with human data to be re.levant. For
example, an animal test that correctly identified carcinogens 90% of the time could
help formulate reasonable public health guidelines. However, as noted .above, ~?st
animal tests do not accurately identify subtle toxic effects. Therefore, an1mal toXlaty
data may be valuable in theory, but in practice they are generally inconsistent and
misleading.
Although most animal models are weak models, strong o~es are possi?le. ~s
mentioned above, certain animal models can reliably pred1ct gross toX1colog1cal
effects. Canaries were once used to test for carbon monoxide in coal mines because
canaries are much more sensitive to this toxic gas than humans. Animal models
can also be useful in studying infectious agents. Although animal models cannot
reliably elucidate mechanisms of disease induction and spread in h~ans, they
have, in the past, afforded strong models for research o~ the. org~m~ms ~hemselves.
To illustrate, rats infected with the syphilis spirochete y1eld httle ms1ght mto
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human syphilis infection. Nevertheless, Erhlich discovered arsenobenzol as a
treatment for syphilis by infecting rats with the spirochete and then trying different
compounds for possible anti-syphilis effect. For Ehrlich's studies, rats served
primarily as reservoirs to harbor the organism, facilitating research on the organism
itself. The many systemic differences between rats and humans did not significantly
undermine his research. Today, in vitro cultures have replaced animals as mere
reservoirs for almost all infectious agents.
Also, animal models may provide information about the species under
investigation because there are generally few major differences in physiological
parameters among individuals of the same species. Most animal experimenters,
however, claim to address human health issues.
Many philosophers of science have distinguished between validating (or
disproving) hypotheses and formulating them.33-35 An animal model cannot be
used to test a hypothesis about humans because differences in causal factors between
the animal model and the human condition render the animal model invalid as a
predictor. The only way to support or disprove a hypothesis about human anatomy,
physiology, or pathology is by studying human beings. Animal-model conditions
are analogues, and it is impossible to validate or disprove any hypothesis by analogy.
Therefore, logically animal models cannot directly contribute to medical discovery.
Medical historian Brandon Reines maintains that animal models primarily
"dramatize" hypotheses about humans without actually validating or disproving
them.
Although animal models cannot validate or disprove hypotheses, they may
function as heuristic devices that assist the process of discovery. 5-7 That is, they may
suggest different ways of conceptualizing problems and thereby help generate new
hypotheses. In this regard weak models have potential value. An unexpected
finding during animal experimentation (including experimentation that was poorly
conducted or that failed to accomplish its original objectives) may lead to an insight.
Such insights, however, can also arise via other research approaches, such as
observing human patients, conducting epidemiological studies, performing in vitro
tests, or engaging in computer or mechanical modeling. Once again then, animal
models do not appear to be necessary for medical progress. In fact, medical historian
Brandon Reines and physician Paul Beeson38 consider the role of animal models as
heuristic aids very limited.
In a review of hepatitis research, Beeson writes: "progress in the understanding and

management of human disease must begin, and end, with studies of man."38
Although much hepatitis research has used animals, Beeson has found that
hypotheses about hepatitis have derived from clinical observations, and that clinical
studies have been necessary to test their validity.38
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Reines observes that nearly all hypotheses about human conditions derive from
human clinical research.36,37,39 Animal experimenters, he contends, pe~form the
superfluous and irrelevant functi~n of ex~~ime~tin? with d~fferent ammal m~dels
until they find one that accords with the climcal fmdmgs: typica?y they then .cla~m
that their model has "validated" the clinically derived hypothesis. _Ofte~, Rem~s
observes, animal modelers highlight confirmatory animal data while discountmg
animal data that contradicts their findings.

IW

Although Beeson doesn't share Reines's conclusion that an~m~l experi~entation is
largely irrelevant to medical discovery, he agrees that most Insights denve from
human studies. Beeson writes,
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"The initial observations of manifestations and courses of human disease
must be made in human beings. The important contributions of
epidemiology depend on accurate clinical definit_ions. The occurrence of rare
sequels or late manifestations is beyond any feasible approach through
experiments on other species."38
Beeson cites progress in understanding hepatitis, ap:pe~dicitis, rheumati~ fever,
typhoid fever, ulcerative colitis, and hyperparath~mdism as representative of most
medical progress in having occurred almost exclusively through the study of
humans.38 Nevertheless, like other researchers who have acknowledged the
primary importance of clinical investigation yet remain lodge~ in the animal-model
paradigm, Beeson continues to maintain the importance of ammal
experimentation. 40-45
The history of polio research illustrates many of animal exper~mentatio~'s strengths
and limitations. Proponents of animal research frequently claim th~t ammal .
experiments were crucial in controlling polio.4,46 J~hn R. Paul'~ re.view of poho
research indicates that animal experimentation faohtated some msights but delayed
others.47
In the 1800s, polio's clinical presentation and natural histor_y ~ere deduce~ from,

bedside observation and post-mortem studies of human victims. Ivar Wickman s
detailed epidemiological analyses of two Swedish epidemics in th~ early 1900s
revealed that mild or even subclinical cases contributed to contagwus spread of the
disease. Most investigators, focusing on polio's life-threatening paralysis,
.
considered polio a central nervous system disease. But Wickman found that poho
affects the alimentary tract (throat, stomach, and intestines) and suggested that the
gastrointestinal system may be the initial site of infection. 48 ,49
By contradicting Wickman's observations, animal data delayed understandi~g of
polio's true pathogenesis and natural history. ~he_ first anim~l ~odel of poho was
developed by Simon Flexner, who induced poho-hke paral!sis m rhes~s m~nkeys
after placing infected human tissue into their noses. Convmced that his ammal
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model precisely paralleled the human disease, he concluded that human polio was
introduced to the brain via the nose and confined to the central nervous system.
For decades, most scientists adhered to this erroneous theory, and this led to
misguided therapeutic measures.47
While animal studies remained the principal focus of polio research in the United
States, Swedish clinical investigators continued to make important contributions.
They tested for the presence of polio in tissues of polio victims and family members
by inoculating monkeys with test samples. H a test monkey contracted polio, the
sample was determined to be infected. The investigators found that polio carriers
could have polio virus present in their throats and intestines up to seven months
after exposure.

'···~
...

Meanwhile, Flexner and other animal researchers continued to study rhesus
monkeys infected with viruses obtained from other rhesus monkeys. This process
selected for more virulent polio strains that tended to infect nervous tissue.
Consequently, the animal mo:lel increasingly diverged from human polio in
pathogenesis and natural history. Systemic differences between humans and rhesus
monkeys undermined Flexner's animal model as a causal model of human polio.
In the 1940s researchers found that polio infection in chimpanzees accords more
cl~sely to the human disease. Like humans and unlike rhesus monkeys,
chimpanzees were found to harbor the polio virus in their alimentary tracts.
Researchers were now more willing to accept the clinically derived hypothesis that
polio infects the human alimentary tract. But this response merely demonstrates
the research establishment's reluctance to accept clinical findings in humans until
parallel findings have been produced--however artificially--in the laboratory in
another species.

~ni~~l models of polio were not very helpful as causal models, and they
sigmficantly delayed development of an effective vaccine. After clinical studies
showed that polio virus infects gastrointestinal tissue, decades of experimentation
on rhesus monkeys suggested that the virus infects only neural tissue. Vaccine
researchers mistakenly believed that polio would only grow in neural tissue, but
vaccines derived from these cultures were too dangerous. In 1948, John Enders,
Th~mas Weller, and Frederick Robbins grew polio on human intestinal tissue,
which led to a safe vaccine. Albert Sabin, who developed the Sabin oral polio
vaccine, has written,
"The work on prevention was long delayed by an erroneous conception of the
nature of the human disease based on misleading experimental models of the
disease in monkeys. "50
Nevertheless, animal experiments may have served heuristic functions by inspiring
new ways of thinking about polio. For example, studies of other central nervous
system diseases in animals suggested environmental roles in susceptibility to
26
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infection. Similarly, studies of TO virus enc~phalitis in mice .r~v.ealed that animals
infected early in life tend to have a more bemgn course: after Irutlal exposure to
.
virus, mice become immune.Sl Researchers reasoned that, b~ analogy, early
childhood exposure to the polio virus might protect most children ~rom paralytic
disease. This would explain why major epidemics tended to occur m remote ar~as,
where populations were too sparse or isolated to permit a~ endem~c .state o~ poho
infection. This insight, surely, did not require animal studies, but It. IS possible the
TO virus research helped scientists conceive this theory. The TO virus model
illustrates the limited utility of weak models.

.

'

Some strong models were also used in the fi~ht .agai~st polio. Swedish investigators
used monkeys to test for the presence of poho vuus m tissue samples; later, ..
researchers used the mouse neutralization test for similar purposes. In. addit.lO~,
monkeys were used in immunological studies that demonstrated multiple distmct
viral strains. In these cases, however, researchers merely assessed whether or not
the animals became infected under different conditions. Today the absence or
presence of a virus in human tissue can be more reliably determined using in vitro
methods.
In theory and practice, animal models generally fail. to reliably predict human
responses to stimuli. While some strong models exist, most ar~ ~eak ~odels of
human responses to stimuli. Weak models may serve ~s heunstlc d~vices and
inspire new ways of conceptualizing clinically relevant I~sues, but t~Is does not
mean that animal models are indispensable analogues directly apphcable to
humans. As merely heuristic devices, animal models are not necessary for progress
in human medicine .

DISCUSSION
Following Dr. Kaufman's talk, Dean Loew stated that it was hard to arg~e :With
much of what was said but asked Dr. Kaufman what he felt about the gammg of an
understanding of human and animal diseases by looking at. animals and their .
uninduced diseases. Dr. Kaufman replied that even observmg naturally-occurnng
diseases can still be misleadmg for human medicine as the animal models are not
the same physiologically as humans. Dean Loew the~ mentioned several ex~ples
where observation of one animal disease or abnormality has led to advances m
knowledge for another animal disease.
At that time it was pointed out by one participant that there is an ~portant log~cal
distinction that must be made--it must be remembered that an ammal model w1th a
natural or induced disease is still merely a hypothesis for the same disease in
humans. The animal is a het~ristic device and the information gathered from the
animal model must be tested in humans.
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Another participant pointed out that not all induced animal models are the same-there is a spectrum of usefulness with some models being strong and some models
being much weaker. Animal models of basic biochemical and physiological
processes (like neurotransmitter action) are stronger models than those of disease
processes. The comment was then made that it is usually just taken for granted that
all animal models are useful. It was pointed out that animals generally prove to be
strong models in toxicology testing.
·
The observation was made that some animal studies are siinply used as a graphic
illustration to dramatize rather than generate or test hypotheses. The use of
primates in studies of violence was given as an example.
It was asked by a participant what would be used if one could not use animal models

and pointed to multiple sclerosis as an example of a disease about which much was
learned from animal studies. Another participant suggested the use of in vitro
cultures or human tissues although it was admitted that animal tissues are more
readily available. Then, based on the results of these studies, animal models and/ or
human studies could follow remembering that models may not always give correct
information and can even undermine an experiment.
This discussion was concluded with the reminder that it is important where one
starts and what are the personal values involved. Researchers can believe 1) that
animal use as models is always good 2) that a variety of approaches is preferable or 3)
models should not be used.
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PUBLIC HEALTH PREVENTION AND OTHER ALTERNATIVES TO ANIMAL
RESEARCH

Neal D. Barnard
Physicians Committee for Responsible Medicine

(The text is developed from the editors' notes. Dr. Barnard's talk was illustrated by a
slide presentation using many graphs, charts, and lists.)
Dr. Barnard began his presentation by pointing out that one of the difficulties with
the continuing animal research debate is that the protagonists not only have
different viewpoints but are addressing different questions and issues. He feels that
the central questions are not how to replace animal experiments but:
1) H animals do suffer, how do we end those experiments? (He stressed that,
when determining the existence of suffering, the effects of confinement
and stress should be considered as well as traditionally-defined pain.)
2) What are the best methods for improving public health?
The term "alternatives" is one that Dr. Barnard would like to retire as it implies that
animal experimentation is the preferred method of research and anything else is
less. In fact, animal use is itself often an alternative-- an alternative to using
humans. He would also like to eliminate the term "biomedical" as it is often used
when there is no true medical connection to biological research .
Dr. Barnard stated that in most cases human cures are not forthcoming from animal
studies - animal research is not solving the problems. He feels it is not necessarily
useful to define the mechanisms of diseases through animal experiments or other
methods. The most helpful studies are human epidemiological studies that reveal
the differences in the conditions of those who have a disease and those who don't,
the risk factors involved, and recommended beneficial public policy changes.
However, we, as a nation, have not yet decided to deal with public health problems.
(In addition, "big" company money and lobbying often conflict with research, e.g.
the tobacco companies and cancer research.) After citing several medical articles on
tobacco written in the 1960s, Dr. Barnard pointed out that if researchers had not used
animals in tests early on, but instead looked at the human condition, they would
probably be much further ahead now. Animal experiments suggested that inhaled
tobacco smoke is not a carcinogen, while epidemiologic studies showed that it is .
On the other hand, animal tests have shown that dietary fat is linked to mammary
tumors in agreement with human epidemiologic studies. In both cases, animal
experiments were interpreted to maintain conservative views. Experiments
suggesting tobacco is not carcinogenic carried political weight, while those indicating
dietary fat have been largely ignored .
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Dr. Barnard presented a series of slides dealing with human dietary studies, which
showed the value of epidemiology to clinical studies. One visual, a graph, dealt
with the relationship of cholesterol levels and risk for coronary heart disease and
showed that a 1% increase in cholesterol leads to a 2% increase in the risk for heart
attack. Other slides revealed the amount of cholesterol in specific foods and showed
that blood cholesterol increases 5mg/ dl, on average, for every 100 mg of cholesterol
in the routine diet. Several slides supported Dr. Barnard's claim that a vegetarian
diet reduces cholesterol. He stated that saturated fats cause the liver to produce
more cholesterol so it is therefore not as helpful as some have thought to switch
from beef to chicken, as skinless chicken has 23% fat content while the leanest beef
has 29% fat. Ovolactovegetarians have lower cholesterol levels than omnivores,
and vegans have the lowest levels of anyone.
In a discussion of heart disease, Dr. Barnard stated there are one and a half million

heart attacks every year in the U.S. and the total health care costs for heart disease is
40.4 billion dollars a year. However, the diet promoted by the American Heart
Association has shown little progress in lowering cholesterol levels while a
vegetarian diet has often been shown to lower the level of cholesterol and to help,
along with other steps, to reverse atherosclerosis. Dr. Barnard stated that researchers
are at times distracted by looking at the microscopic aspects of this disease rather
than the overall picture which would indicate a need for obvious changes such as
diet.
Breast cancer also appears to be related to dietary intake of fats. A slide revealing
data on breast cancer indicated a direct correlation between fat intake with death
rates from breast cancer. The same appears to be true with prostate cancer. Another
slide illustrated that both dietary fat and body fat result in increased estrogen
production which is believed to increase the risk of breast cancer. It appears that
factors that increase survival from breast cancer include low fat intake, low body
weight, and high fiber, carbohydrate and beta-carotene intake.
D~.

Barnard's slides illustrated how cancer rates overall in the U.S. have gone up
shghtly between 1960 and 1985, with cancer death rates having risen dramatically for
lung cancer, risen slightly for breast cancer, held roughly even for prostate cancer,
and dropped for colon cancer. Every year in the U.S., 1,170,000 cases of cancer are
diagnosed and 526,000 people die of cancer. Cancer treatment costs 35 billion dollars
a .year. Ho~~ver, while traditional diagnostic techniques such as mammography are
highly pubhozed, the connection between diet and cancer is rarely discussed .
Hypertension treatment costs the U.S. 12.5 billion dollars annually and diabetes
treatment costs 6.8 billion dollars annually with 10 to 14 million Americans
suffering from diabetes.
~r: Barnard does not suggest that changed life styles will help everyone but states it
1s mcongruous that the U.S. government continues to promote the eating of meats
and dairy products even though epidemiological and clinical studies suggest links
between these products and disease. Cows' milk can encourage the onset of
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juvenile diabetes. He then explained the difficulties associated with gaining
widespread acceptance for the new "four food groups"-- grains, legumes, vegetables
and fruits.
Dr. Barnard concluded by restating that it is not useful to think of prevention as an
alternative to animal use. However, animal studies distract us from vital research
and lead us away from making important lifestyle decisions.
DISCUSSION
In the discussion following his talk, Dr. Barnard was asked what he feels is the better

investment for the dollar. He replied that the wiser expenditure was for studies of
life-styles and that animal experiments are a poor investment.
Dr. Barnard stated that there is new trend that concerns him-- the "dissecting" of
diets in healthy cultures to find a "magic bullet" followed by the testing on animals
of the suspected "bullet." These experiments are simplistic and unnecessary.
He was asked to comment on the lack of public reference to vegetarians and vegans.
He replied that some members of the public are still resistant to vegetarian diets. A
representative from Tufts Veterinary School pointed out that possibly there is a
change on the horizon as, at the 1993 graduation dinner, 20% of the graduating
veterinarians choose a vegetarian dinner compared to 2% in earlier years.
When asked if he would deny people other treatments, he replied that he would
not. People who will not make lifestyle changes cannot be denied treatment and
despite best efforts, people still get sick with non-preventable diseases. However,
people are not doing enough to make even the simplest changes even though there
are certain identifiable factors that can get people to change their diets. There is a
definite need to study behaviors and encourage cultural changes. Animal
experiments, he felt, are not the keys to prevention or to treatment.
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RESPONSE TO THE PRESENTATIONS
Kenneth J. Shapiro
Psychologists for the Ethical Treatment of Animals

(Text received from Dr. Shapiro)
Dr. Shapiro organized his response to the several papers under four headings:
ethics, science, the concept of animal model, and costs/benefits analysis.
L_ Dr. Shapiro began his response by observing that the title of the seminar, The

Value and Utility of Animals in Research, presupposes a utilitarian viewpoint or
ethic. However, this philosophy is only one of several competing philosophies in
the current debate and one that is frequently criticized for failing to preserve the
interests of the individual. Further, it is a philosophy which scientists, who do not
like to think of themselves as talking about ethics, implicitly adopt. For
utilitarianism allows them to apply ethical considerations using the familiar
scientific language of measurements and results. However, despite the adoption of
utilitarian talk about costs and benefits, in reality, scientists rarely actually do a
cost/benefits analysis in anything approaching the rigor of scientific measurement.
They also fail to recognize the complexities and problematics involved with
applying such a calculus to evaluate animal research.
In any case, having invoked utilitarianism, the title leaves out the "costs" side of

that ethic.
While realizing that the focus of this seminar is not the ethical but the scientific
issues in the current debate, Dr. Shapiro presented his view that to achieve basic
change, attitudes must change, and discussion of ethics is a primary vehicle for
achieving it. More insidiously, "value and utility" talk can be an attempt to sidestep
and downgrade the role of ethics by framing the issue as strictly a scientific question
that must be answered by scientists in scientists' terms. However, many thinkers
believe that the attitude or ethic regarding the value of nonhuman individual
animals is of more consideration than any argument about utility and how to
measure it. Garner says:
The debate then is .... not exclusively (or even mainly) about facts but is about
the differing perception of what should be regarded as unnecessary suffering-which are inextricably linked to the moral status of animals.
A primary datum is that some people value animals and some do not.
2. The purpose of this remark is not to downgrade science but to restore it to its
proper role. While science is incredibly resourceful, it is not what we thought it
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was. The traditional view of science has been challenged in recent years by
philosophers, sociologists and historians of science.
The traditional view, referred to as positivism or modernism, featured a naive view
of reality in which the scientist was a detached observer who could directly observe
the facts and apply logic to them to arrive at the truth. By contrast, in the
constructionist or postmodernist view, science is a socially-constructed enterprise.
~ much as it might espouse an ethos of logical empiricism, the scientific enterprise,
hke any other complex social institution, in practice is a competitive, conflictual,
political and generally messy affair.
ln~dentally, when applied to animals in the lab, this philosophy and sociology of
soence results in the view that the lab animal is itself a construct--that a distinct
category of animal has been created--the animal not as individual or even member
of a species, but as a receptacle for disease, an instrument, a preparation.

In the postmodernist view, sdence's insistence that there is just one way to reach
the truth, that if we follow certain procedures we can be assured (positive) of the
~alidity o~

our results, is displaced with the more pragmatic notion that the ways are
mexhaustible and no one method has primacy. Science is a human project in which
many approaches and alternatives are available.
Thi~

new view of science has ethical implications. Science is a human project in
which there are choices and options. Science has no special status that somehow
places it outside the present and changing values and needs of society. As with any
other social practice, it is not within the purview of science to decide the ethical and
policy issues that frame its own practice. In the final analysis, the public must decide
the limits of any institutional practice, including the practice of science.
The thrust of the postmodernist view of science restores science to its proper role,
recognizing it as a social enterprise that is a particular set of methods of trying to
understand things. It has no special access to the truth and is subject to the same
individual foibles and institutional faults as any other human enterprise.

3... In responding to Dr. Kaufman's presentation on scientific problems with animal
models, Dr. Shapiro outlined four concepts of animal models--the animal as a host,
as a causal analogue (strong analogy), as a heuristic analogue (weak analogy) and as a
rhetorical device. His thesis was that contemporary animal models at best operate as
heuristic devices and, at worst, as mere rhetorical devices. Notwithstanding this,
various professional associations and individual scientists make the stronger claim
that animal models provide causal analogues.
The idea that an animal model could provide a causal analogue of the target
phenomenon--that is, an exact duplication of the mechanism producing it-originated in the late 19th century with Koch and others. The germ theory of
disease in which the investigator infected an animal with a pathogenic bacterial
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organism led to the notion that the animal is simply~ recet:'tacle fo~ the target
phenomenon which is recreated identically in the animal site. TB IS TB. !he
animal model then, in this view of disease, duplicates the causal mechanisms of
the human p;thology. Both contemporary diseases, which are not primarily
infectious or germ entities and contemporary theories such as systems theory and
chaos theory show that the simple idea of the animal as host or receptacle for a
phenomenon simply transported to a different species site is wrong-headed.
Animal models do not duplicate the causal relations of the original phenomenonthey are properly conceptualized as heuristic devices-ways of generating ide~ and
insights. These ideas must eventually be appli~ in the human co~text .. This
application is not so much a validation as a testmg of whether the Idea IS useful.
(For example, ideas that suggest differences between animal and hum~n-based
phenomena may be useful, although not '.'valid.'? The claim that ~Imal models
provide a site in which the causal mecharusm of mterest .can be duphca~~d and
discovered is anachronistic, and needs to be understood m terms of political and
public relations consideration.
There is misuse of even this proper heuristic function of animal ~~els. F~r
example, in psychological research, this misuse of t~e pr~per heu.~Istlc func~10n of
animal models is evident, as often a strong analogy IS clrumed, a hypothesiZed
parallelism of causal relations" emulating the natural ~ci.ence. J:Iow_ever, on ~ts face,
when using animals to study such things as drug addiction, antlsooal behavior, or
eating disorders, causal relations cannot be exactly dup~icated. Oft~n animal ~<>?els
in psychological research do not even have the less stnn&ent fun~t10n of providmg
a heuristic device. Rather, their use is limited to a rhetoncal device. The model
provides something closer to a graphic image than a discovery of a causal
mechanism. There are other problems with the use or misuse of animal models.
Too often validation is ingrown as it is limited to comparing researc~ on a model to
other research using the same model. This criterion of internal consistency also
applies within certain literatures: "cat people" do not cite "rat people" let alone
"clinical people."
In addition to the use of animal models as simply relatively loose analogies,
sometimes there is a reversal in the proper relation of the model and the targeted
phenomenon. Researchers begin with an insight gained in a human clinical setting
and then construct an analogy to it through an animal model. A backwards
confirmation is then required. The status of animal models is such that facts are
only facts if they are proven in the laboratory with animals. In this use, the model's
heuristic function is limited.
Recognition of the limits of proper use of animal models places a considerable
ethical burden on the researcher. For example, arguable, highly invasive is
unacceptable given this limited function.
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!.. In regard to Dr. Rowan's comments on the problem of costs/benefits (C/B)

The same lip service is employed in touting benefits. In his article, Miller simply
lists animal models of human disorders and includes sweeping generalizations
about beneficiality. There is no application of rigorous case-by-case scientific or
historical evaluation, and the generalized claim of benefits provided in such
catalogues is paltry taken again~t the larger body of nonanimal psychology research
with its relatively more direct application to human welfare.

analysis, Dr. Shapiro took the general position that researchers currently are not
using the several available scientific measures of invasiveness. In any case, in his
view, there are inherent limitations in a purely scientific assay of C/B. The
limitations follow from the heuristic function of animal models. It is clearly a
problem of historical interpretation whether any particular animal model and, as
well, whether animal models as a general research strategy, have generated useful
applications and understanding compared to other particular nonanimal studies
and general strategies.
Dr. Shapiro disagreed with Dr. Rowan's data on animal use which show that less
than a majority of animals experience severe suffering. For the data is limited by
the amount of information provided, particularly in the U.S., and by the
information's reliability.
Dr. Shapiro took issue with Dr. Rowan's suggestion that if 40% of studies use
animals, then we ought to giv~ such research 40% of the credit for benefits. He also
challenged Dr. Rowan's view that the clinic and the animal laboratory are an
endless circle of reciprocal influence and that the taking of any one portion of this
circle results in losing more than the portion removed. Dr. Shapiro stated that the
mutual influence is minimal as the two typically do not cite or even read each
other, and, when they do, the influence of what the clinic takes from the laboratory
is largely rhetorical and often misleading.
He elaborated on this point in the case of psychological research, and particularly an
article by Neal Miller referred to by Leader and Stark. Miller makes a case for the
value of psychological research. Dr. Shapiro pointed out that Miller, a behaviorist,
and others in psychology, stress that the benefits of animal use are high while the
costs are low. They employ such utilitarian language because it is sympathetic to
science with its heavy emphasis on instrumentalism. Behaviorism itself places
emphasis on utilitarian notions of reward, pleasure, reinforcement, etc. In fact, the
doctrine of psychological hedonism as a driving motivational force is the child of
Bentham.
But, Dr. Shapiro states, this is lip service utilitarianism only for Miller and others do
not present any scientific data on C/B. In place of providing results of a measure of
the costs of a given study or animal model, there is a global denial that pain is
involved in psychological studies. However, there are available several rating scales
which measure the "degree of invasiveness" and other components of the "ethical
costs." In a recent study on attitudes toward and the use of analgesics in 23
biomedical laboratories, Phillips (1993) documents the denial of pain by laboratory
investigators and shows that the data often used to argue the absence of pain,
according to the USDA annual reports submitted by the primary investigator, are
not reliable. Dr. Shapiro stressed that psychology can not claim, as it does, to have
developed animal models for virtually every conceivable harmful, distressing
and/ or painful human condition and yet deny that animals are suffering.
38
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Further, two sleights of hand are apparent. In place of a serious and rigorous
assessment of the worth of a particular published or proposed study at the IACUC
level, there is offered a global evaluation of the entire enterprise of animal-model
research. A second sleight of hand is the disingenuous use of scientific findings
beyond their proper purview. The simple presence of an animal model on a
particular fopic itself provides no scientific evidence of the benefits of that research.
Although they provide no test of the null hypothesis of beneficiality, they are
presented as if they do. However, Kelly, in a citation analysis of the Journal of
Consulting and Clinical Psychology and Behavior Therapy, found that animal
models are not readily cited.
Dr. Shapiro stressed that historical considerations are critical, beyond any scientific
assessment of C/B. A reading of the history of science is required to judge true costs
and benefits. Many animal studies are incomplete or unpublished (publication
rejection rates are 70% to 80% for psychology studies compared to 50% for other
sciences). These are costs without benefits. In addition, of those animal studies
published, few are cited in anything other than animal literature.
There is also the problem of historical evidence and historical interpretation. True
assessment of the actual role of the model in any purported "benefit" is needed. Did
the model suggest a new understanding or treatment or did it simply add a graphic
image or legitimate stamp of approval? In psychology, animal model research
rarely results in specific technical innovations or applications.
But this is not to say that animal research has not had an important influence on
the directions taken by modern psychology. Which of those directions are
beneficial, which are delays and which are misleads? For example, in the heyday of
behaviorism (the 1940s and 50s), a significant proportion of a generation of research
psychologists trained in and conducted animal-based research. If they had, instead,
directly investigated human behavior, would behavior therapy have advanced
more rapidly as Drewitt and Kani contend (in Sperling, 1981, p.197)? When
psychologists learn sophisticated laboratory animal experimental techniques, their
careers have a certain trajectory which usually precludes learning sophisticated
human-based experimental techniques. Further, having learned surgery and other
invasive techniques on animals, that is what they teach to the next generation of
research psychologists. Those who invest in the strategy of developing animal
models and those who would have taken their places in the research enterprise
would have produced their own research. These roads not taken, these unrealized
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benefits, are then costs. Every time one project is chosen for funding, others, that
also have associated costs and benefits, fail to be funded.
Science is determined by the philosophy of the science that frames it and the
methods it employs as well as by the objects under investigation. The construction
of the laboratory as the site and the laboratory animal as the object of study and the
adoption of the animal model strategy strongly affected the kinds of questions
investigators asked. In turn, these affected the kinds of answers and the kinds and
power of applications derived. What is the limiting effect of framing research
questions in terms of the construction of an animal model? What are the effects
when that animal-model strategy is joined to a behavioristic approach which deemphasizes the study of consciousness? Did this have an impact on the recognition,
measurement and ethical consideration of pain and suffering of laboratory animals
used as models or on the degree of suffering allowed to be imposed?
In his book, Man and Mouse, W. Paton confirms the need for a historical method in
assessing the costs and benefits of animal research. He offers the test of deletion and
applies it by a thought experiment in which we are to suppose that no animal
experiments had taken place for the past 2000 years. Dr. Shapiro feels that he is
being generous in taking this proposed method seriously. Paton's historical method
substitutes nothing for that which he deletes. Of those scientists who did invasive
laboratory animal research, some would have studied humans directly and some
would have studied nonhuman animals in noninvasive ways. Rather than leaving
a gaping black hole in place of the deleted invasive laboratory animal research, Dr.
Shapiro asked why it should not be replaced with 2000 years of more careful and
respected clinical and epidemiological research, with 2000 years that led to the much
earlier development of more sophisticated imaging technology that allows us to see
human pathology. And on the animal side, with 2000 years of Jane Goodalls --Jane
Goodall of the dog, the tree shrew, the Norwegian rat, the field mouse, the octopus,
the starfish. What would have been the benefits of animal vivisection; what would
have been the costs? This is the historical problem of interpretation.
Dr. Shapiro concluded his response with the appeal that if we are going to use
utilitarianism, let's do so genuinely and intelligently as we judge a particular study
and the entire enterprise. Let's recognize the limits of science in its own practice
and as judge and evaluator of its own practice. Let's get the help of professional
historians. Ethics and attitudes, particularly attitudes toward the status and value of
animals, is the critical criterion and engine of change. There are better ethics
available than a utilitarian one, certainly a utilitarianism that forgets that it is an
ethic and masquerades as a scientific question--one that only scientists can answer .
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RESPONSE TO THE PRESENTATIONS
Martin L. Stephens
Department of Laboratory Animals
Humane Society of the United States

(Text developed from editors' and Dr. Stephens' notes)
Dr. Stephens began his presentation by underscoring the importance of ~s
workshop. He remarked that there is surprisin~l~ ~ittle scholarly analyslS of the
value and utility of animals in research. The cntlasms leveled by an1mal r~search
critics have not been seriously addressed. The animal research controversy 1s
.
sometimes called a debate, but there really is little debate. Instead, what we have 1s
polarizing rhetoric and public-relations posturing. This creates an adversarial.
climate which, alas, dilutes the impact of well-intentioned ventures such as th1s
meeting.
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In this climate, some animal research proponents openly implore scientists to tout
the importance of animal experiments to their work. Such propagandizing can
skew later analyses of the contribution of animal experiments to modem research
advancements.
While supporting the aim of the workshop, Dr. Stephens ~xpr~ssed his reluct~ce to
engage in an analysis of the value of animal resear~h t~at IS d1vo~ced from ethical
and humane considerations. Such compartmentalization of the Issues, though
valuable for purposes of today's workshop, cuts against the grains of reformers, who
typically argue that ethical and humane considerations should be at the forefront of
discussions of animal research.
In Dr. Stephens' view, determining the historical value o~ ~imal. e~peri~ents in
different fields of research is complicated. A full set of gmdmg pnne1ples IS needed .
superficial approaches to the subject abound, with the most unhelpful and
disingenuous, yet most common, being the mere listing of supposed advance that
resulted from animal research.
Dr. Stephens distinguished two perspectives in historical ana~yses of scie~tific
advances. The most common perspective traces the key studies/ obser~at10n~ that
led to the discovery in question. The other perspective adopts a more mclus1ve and
long-term view by identifying the key methodological/technical innovations that
enabled scientists to carry out the critical studies leading to the discovery (see
Comroe and Dripps, 1981). Animal research proponents typically adopt the former
perspective when touting the alleged contributions of animal research. However,
they fall back on the latter approach when animal experiments played no obvious
role in a major discovery but may have played some role in the development of the
technology that facilitated the discovery .
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Dr. Stephens agreed with Andrew Rowan that Dr. Rowan's paper and talk were
provocative. Dr. Stephens had anticipated that Dr. Rowan would critique the
establishment view of the overarching importance of animal research, a view in
great need of closer scrutiny. Dr. Stephens accused Dr. Rowan of coming close to
being guilty of some of the same sins as animal research proponents. Rowan's
recounting of the Elizabeth Hughes story (detailed in the pre-conference readings)
plays on public sympathy for the sick.
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Dr. Rowan mentioned the scientific skepticism that greets human epidemiological
findings, but there would be fewer skeptics if not for the irrational stranglehold of
Koch's postulates on scientific thinking. In his own work, Dr. Stephens has tried to
demonstrate the historical importance of alternative methods (see Readings). More
effort should be put into research and development of such alternatives. Given the
capabilities of human-centered research, we now need to examine critically the role
that remains for animal models.
Dr. Stephens agreed that the isolation of insulin (referred to in previous talks and
pre-conference readings) was a great triumph, but called attention to Dr. Rowan's
statement that non-animal methods probably would have led to the discovery of
insulin a year of two after Banting and Best's work. This reveals the simplistic
nature of Paton's test of deletion (see below).
Dr. Stephens agreed with much of Dr. Kaufman's presentation. He himself had
reached many of the same conclusions in his own analyses, particularly with regard
to the dramatizing function of animal modeling (Stephens, 1986). For the most part,
animal research proponents have conveniently ignored the scholarly work of Dr.
Kaufman and his colleagues and dismissed these individuals as antivivisectionists.
Dr. Stephens felt Dr. Barnard's presentation was important for calling attention to
the "big picture" -the health benefits resulting from life-style changes and a
preventive approach in health policy rather than the current emphasis on research
directed at treatment after disease has already taken hold.
In Dr. Stephen's view, if Drs. Kaufman and Barnard's analyses are on target, the
policy implications for public health in general and animal research in particular
would be profound. The scope of animal research would be greatly diminished and
much greater emphasis would be placed on human-centered work. Where such
work would be limited by technological constraints, resources should be marshaled
to expand the capabilities of these non-animal approaches.
Dr. Stephens described William Paton's analysis of the value of animal
experimentation (in Man and Mouse, Animals in Medical Research) as surprisingly
weak. Dr. Paton implies that studies of animals probe facts about humans, which is
illogical. Paton's main principle, the "test of deletion," is superficial and guaranteed
to inflate the importance of animal research. It ignores the historical issue of
whether alternative methods could have achieved the same result as the animal
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experiments in question. The deletion test also ignores cases in which animal
experiments were more harmful than ~elp~ul: i.e., Pa!on trumpets all~ged s~ccesses
f animal experiments but ignores the1r fallures. Ammal models of 1schenuc
~troke, for example, have sent researchers scurrying after 25 false leads on treatment
possibilities (Wiebers et al., 1990).
Dr. Stephens concluded by commenting on two of. the workshop read~ng~ ~at came
to different conclusions based on the same data: his own paper (The S1gm~1cance of
Alternative Techniques in Biomedical Research: An Analys1s of Nobel Pnze
Winners) and one by R. Leader and D. Stark (The Importance of Ani~~s in.
Biomedical Research). Dr. Stephens chided Leader and Stark for not a.ting hlS _paper,
much less addressing the apparent conflicts between the two papers. He ex~lamed
that the aim of his paper was not to analyze the historical importance ?f arumal
research, but to devaluate and demonstrate the importance of alternative
techniques. He feels he accomplished this. One the other hand, Leader and Stark set
out to demonstrate the importance of animal research. Dr. Stephens accused them
of inflating the importance of animal research by defining ~uch research overly.
broadly. In the animal research category, Leader and Stark mclude~ research usmg
invertebrates, in vitro cultures, and tissue from slaughterhouse arumals. The t~rms
of reference of the animal research controversy indicate that such research falls mto
the alternatives category.
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THE MISREPRESENTATION OF EVIDENCE BY THE ANIMAL RIGHTS LOBBY

Jack H. Botting
Research Defence Society, London, UK

(Dr. Botting provided the following text upon which his talk was based)
The contention between the protagonists of animal experimentation as a means of
alleviating human and animal suffering and those that oppose such research has
reached a totally sterile phase. The views of each group are polarized. From one side
animal experimenters are held to be profit-driven bigots, adhering to old-fashioned
methods of research. From the other, antivivisectionists are viewed as naive,
scientifically ignorant individuals, upon whom no time should be wasted in
attempting to explain the need for certain experiments since it would not be
understood.
Of course, both views are incorrect. It must be acknowledged that there are some
experimenters who manifest arrogance in considering themselves above the need to
justify their work to the concerned laity. This is unacceptable--everyone in society
must be held to public account and be made aware of public concern. Nevertheless,
the opponents of experiments upon animals undoubtedly contribute to this hard line
attitude of the experimenter, and this talk attempts to describe how, in the hope that it
may play a part in producing an improvement in mutual understanding.
The problem stems from the rhetoric used by the animal rights (AR) lobby, and the fact
it misinforms the lay public about the historical and current value of animal
experiments. I would like to give some examples.
My interest in this issue was stimulated after reading the press release (in January,
1991) to mark the formation of a new organization with acronym LIMAV, which is
from the French title of the International League of Doctors against Vivisection. The
press release stated:
"The majority of doctors now accept that experiments involving animals are
of no practical value: no lives have been saved, no new cures have been
developed and no breakthroughs have been made by scientists using
animals."
Additional statements in the press release claimed that LIMAV members include
some of the world's leading doctors. Remarks such as this, apparently from an
authoritative source, obviously encourage members of the lay public to challenge the
contribution of animal experimentation to medical research. They believe what they
want to believe. This is evidenced by the spate of letters to local newspapers in the UK
which contain comments such as:
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hundred. years of animal experiments have produced an endless stream
of highly profitable drugs, countless human tragedies, but not a single cure."
(Letter to Derby Evening Telegraph 8/27 /93)
"Vivisection is, after all, a medical fraud. No animal experiment has ever
had any human benefits, in fact it has hindered medical progress throughout
history." (Leicester Mail 9/16/93)
The U~ V statement ~s of course untrue. During the period in which I worked as an
academic pharmacologist, I have seen some striking improvements in therapy that
stemmed from animal experimentation.
MALIGNANT HYPERTENSION
As a student I remember being told that if one was diagnosed as having malignant
hypertension, then one's. life expectancy was less than one year. Death would certainly
be preceded by dev~st~tmg headaches and possibly blindness. Then, in 1950, William
Paton a~d Nora Zrumis (1), through animal experiments, demonstrated the interesting
properties of the polymethylene-bistrimethylammonium salts. Some of these
possessed muscle relaxant properties (which later Paton tested on himself and which
were ~ubsequently used in surgery and tetanus). Others of the series were ganglionic
blocking drugs that were shown to be potent at lowering an elevated blood pressure.
These drugs were very soon used in malignant hypertension and were life-saving.
Ho~e~er th.ey were not perfect drugs. They were poorly absorbed after oral
admmist~atlOn, they caused constipation, blurred vision and in fact prevented all
auton.omic reflexes. But encouraged by the therapeutic success of the ganglionic
blockmg drugs, other drugs were produced; reserpine, diuretics, alpha-1 blockers beta
blockers ~d ACE ~nhibitors that gradually rendered the treatment of malignant'
hyperte~s10n effecti~e and relatively benign. Today I doubt if any pharmaceutical firm
runs anti-hypertensive program since the present treatment is effective and mostly
free of side effects. Drugs come off patent and treatment becomes cheap.
TREATMENT OF PEPTIC ULCER
A second, indisputable example of improvement in drug therapy has been in the
treatment of peptic ulcer. :rior to the deve.lopment of the histamine H 2 receptor
blockers, treatment of peptic ulcer was by diet, antacids, atropine-like drugs which, of
course, h~d a m~ria~ of unpleasant side effects. The H2 receptor antagonists "cured"
t~e ulc~r m that It disappeared but tended to return if drug treatment was
d1scont1~ued. Proton pump inhibitors prevented acid secretion at a more distal
mechanism and .seemed to be as effective. Treatment of this condition appears to be
set f~r a d.ramatic change however, with the apparent demonstration of the
rel~tionsh1p between helicobacter pylori infection and peptic ulcer. Removal of the
hellco?act~r apparently can cure .the ulcer. A vaccine has now been developed that is
effective~ .a mous~ mode.l and IS at present undergoing trials in patients. If, as
app~ars, 1t 1s effective, a s1mple one-off vaccination will obviate the need for
contmuous drug therapy.
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These two examples of the development of effective drug treatment dearly disprove
the statement by LIMAV.
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TREATMENT OF INFECTIOUS DISEASE
Further refutation can be obtained from other fields. Arguably the most striking
advance in medicine has been the treatment of infectious disease-to the serious
medical historian an outstanding example of the value of animal experiments. Yet, in
the UK, we see many, many letters to the local press that repudiate this, citing
improvements in sewage disposal, purer water supplies and better nutrition as being
responsible for the conquest of destructive epidemics. Is this true? In my infancy, the.
importance of purity of water supplies (and hence of proper sewage disposal) was well
accepted, as was the need for aseptic technique during operations and the general
cleanliness of wounds to prevent putrefaction. Yet three people within my own social
circle died of septicaemia, including my first general practitioner.
Apart from anecdote, there are statistics which are familiar. Up until the 1930s, for
every 100,000 live births, 200 women were dying of childbed fever (streptococcal
infection), 60 in every 100,000 men between 45-60 were dying of lobar pneumonia.
These deaths were dramatically reduced between 1935-40 because the German
pharmacologist Domagk showed that a dye, prontosil, could protect mice against a
lethal inoculum of streptococci (although it did not affect streptococci in culture) .
From this simple animal model the therapeutic use of prontosil was established, and
consequently the sulphonamide drugs. Soon after came penicillin, the antibacterial
value of which was also established using streptococcal-infected mice. It was the
discovery of these antibacterial substances that reduced deaths from bacterial infections
to low levels.
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Vaccination reduced deaths from tetanus and pertussis, animal experiments were
necessary to establish the lack of virulence of the formalin or heat-treated toxin or
whole cell preparation. Since it is readily preventable by appropriate immunization,
tetanus s~~uld be a rar~ disease. It is thus a shameful situation that even today well
over a million people d1e of tetanus per year, and the disease accounts for 50% of all
neonatal deaths (2).
Diphtheria has also been conquered, firstly, through the production of an antitoxin
secondly, by immunization. The development of both depended on experimental'
work on guinea pigs. This achievement has also been challenged by the animal rights
lobb.y who use sta~stics for the incidence of the disease in various countries to attempt
to disprove
the eff1cacy of vaccination. The statistics used however, were those of
.
var1ous European countries during and just after the 1939-45 war, when, because of
mass troop. and civilian movements across Europe, counts of percentages immunized
were unrehable. The recent re-emergence of diphtheria in areas which have been
~lear of_ the disease for many years serves to emphasize the continuing need to
1mmumze and maybe re-immunize.
Up to the middle of the nineteenth century, smallpox was a devastating disease killing
1 ~ ~0 persons, affecting nearly everyone, leaving many scarred. Smallpox was
e~1mmated from Europe and the USA in the early part of this century using vaccinia
Vl~ gr~wn on the skin of calves. An aggressive smallpox surveillance and
vaccmat10n program has resulted in the eradication of the disease from all countries.
The last case was recorded in Somalia in 1977. Now the discussion is simply when and
if the stored virus should be destroyed.
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At present every year in the UK 50 million prescriptions for antibiotics are filled,
which would hardly suggest that infectious disease is a thing of the past, a
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phenomenon that disappeared with our increase in living standards. The point surely
is made that social changes could not solely be responsible for the control of infections.
POLIOMYELITIS
Poliomyelitis is a particularly good example to illustrate both the value of animal
experimentation in the dramatic reduction in mortality from an infectious disease and
also to illustrate how scientific fact can be blatantly misrepresented to the anger and
consternation of biomedical scientists .
One of the leading antivivisectionists in the UK is Vernon Coleman, a graduate in
medicine and one-time general practitioner, but who, for the last 20 years or so, has
made a living by writing popular books about medicine and simple articles on medical
matters and antivivisection in what are called the "tabloid" newspapers in the UK
(popular newspapers that have a large circulation). Thus one must acknowledge that
Coleman has a considerable influence. He is also the present president of LIMAV and
he has written a book decrying animal experiments called Why Animal Experiments
Must Stop (3). Here is a quotation from this book that refers to the story of poliomyelitis with regard to animal experimentation.
"As with other infectious diseases, the significance of poliomyelitis had dropped

as better sanitation, better housing, cleaner water and better food had been
introduced in the second half of the nineteenth century."
Coleman thus dismisses any contribution by animal experiments to the reduction of
deaths from polio since he claims that polio was already beginning to wane at the turn
of the century. This is the complete reverse of reality. Poliomyelitis was a rare and
sporadic disease until the end of the 19th century, its occurrence until that time
usually merited a write-up of the case as a rare example of paralytic disease. Then
there was a series of devastating epidemics of infantile paralysis. Where did these
epidemics occur? In underdeveloped countries? On the contrary, in those countries
with the highest standard of living, Scandinavia and then the USA.
Relatively minor epidemics of between 14 to 44 cases occurred in parts of Norway and
Sweden during 1868-1887. The disease became epidemic in the USA in 1893 when 23
cases occurred in Boston. The size of the epidemics began to increase with an outbreak
of 132 cases in Vermont (1894). Then came the era of regular epidemics: 1031 cases in
Stockholm (1905) and 750-1200 cases in New York City in 1907. From that time on
there was a regular background incidence of the disease with periodic, dreadful
epidemics (4).
The reason for this sudden transformation of polio from a sporadic disease is of course
obvious. If contracted very early in life, polio is a relatively mild disease, like a mild
influenza (presumably, due to the persistence of maternal antibodies). However, this
mild attack stimulates an active immune response and one is thus protected against a
further exposure. Therefore, children brought up in primitive conditions are likely to
be exposed to the virus early in life and will be immune .
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As living standards are raised children are not exposed to the enterovirus and, should

the virus then infect someone, the disease will spread very rapidly through a
susceptible population. This point is very nicely shown by comparing the relationship
between infant mortality (the best indicator of the standard of living) and incidence of
poliomyelitis. Prior to 1950, countries with a high mortality had a low incidence of
polio. Those like Sweden, with an infant mortality rate of less than 25 per 1000 births,
had a high incidence of the disease. One contemporary epidemiologist observed that
when a country reduced its infant mortality rate to less than 75 per 1000, it would
endure a polio epidemic within five years (4).
·
Since the readily available data clearly shows that polio emerged as a widespread
medical problem at the turn of the century, one must ask how is it that the president
of LIMAV, Vernon Coleman, got the story so completely wrong in his book.
Did animal experiments contribute to the control of polio? From 1900 through 1950
everything we learned about the polio virus was derived from experiments on
monkeys. In 1908, Landsteiner, later to receive the Nobel Prize for his work on blood
grouping, showed that polio was caused by a virus by taking bacteria-free extracts from
the spinal cord of a boy who had died of polio and injecting them into monkeys who
subsequently succumbed to the disease. (I~terestingly, Landsteiner gave up working
on polio since his lab could not afford to maintain a monkey colony. It was for this
reason he switched to working on blood groups.)
Similar techniques showed that the virus was harbored in the nasal, buccal and
intestinal membranes. Of great significance was the demonstration that nasal
washings taken during an epidemic from persons with no sign of the disease were able
to produce paralysis in monkeys (thus showing that some. people were immune).
Monkeys continued to be necessary up until the time it was proven that the human
diploid cell line could be used to grow the virus and hence prepare the vaccine .
The second piece of blatant misinformation in the book by Coleman was that
vaccination was not a success, ostensibly backed up by statistics, for the incidence of
polio in two states pre- and post- vaccination:
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"Proof that the introduction of the vaccine was not the success it was made out
to be comes from undeniable statistics. In Tennessee, USA, the number of
poliomyelitis victims the year before vaccination became compulsory was 119,
but the year after vaccination was introduced the number rose to 386. In North
Carolina the number of cases before vaccination was introduced was 78, while
the number after vaccination became compulsory rose to 313." (3, pp. 64, 65)
The biased selection of data, of course, is not scientific evidence. Certainly statistics for
mortality shows a clear beneficial effect of vaccination for these two states.
At a national level, mortality statistics for polio show an indisputable fall consequent
upon vaccination in both the USA and England and Wales. The World Health
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Organization (WHO) eradication program has now been underway for some years.
South America has had the disease eradicated and the WHO program plans the worldwide eradication of the disease by the turn of the century.
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Polio had virtually disappeared from the western world, save the occasional outbreak,
every five years or so, of a few cases in the Netherlands. These occur always among
members of a Calvinist sect who disagree with vaccination on religious grounds.
The vaccine was originally prepared from virus grown on monkey kidney cells, and it
was safe although one had to go to great pains to exclude simian viruses. In 1962, with
t~e development of the human diploid cell (HDC) line, it became possible to grow the
v1rus for the preparation of the vaccine in human cells. It might be claimed that there
was ~xcessive and unnecessary slaughter of monkeys to provide kidney cells to grow
the v1rus, and I would have to agree. This was simply because the acceptance of HOC
line as a medium for growing virus was slow in coming, particularly in the USA,
w~ere there were .some fea:s that the HOC might cause leukemia and also the general
att1tude was that 1f something worked, one shouldn't change it. It wasn't until
millions had been immunized with HOC vaccine in UK, Yugoslavia and USSR that a
license was granted in the USA in 1972.
~us

we can now prepare the vaccine without the need to kill monkeys to obtain
kidney cells although the live, attenuated vaccine must be tested for lack of virulence
on monkeys. That is an example of modern developments gradually obviating the
need to use animals, something which all experimenters would applaud.
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SPECIES DIFFERENCES
The second example of misrepresentation by the animal rights lobby is its contention
a?<>ut species differences--"animals aren't like us," "they suffer from different
d1se~ses," etc. It is dangerous, it is maintained, to rely on animals since they cannot
predict whether a drug will be toxic in humans.
This line of argument of course is based on a total misconception of the procedure
~ollow_ed, ~nd indeed legally required, before a drug is marketed. The premarketing
n~veshgahon of a drug actually involves humans to a greater extent than animals.
~~r~tl:y, there is a detailed investigation of its effects in maybe 50-100 normal
md1v1d~als (P~ase 1 trials). During Phase 1 volunteers are closely monitored. A daily
blood Plc:tU:e 1s examined and kidney and liver function are measured by appropriate
tests. This 1s followed by an investigation, in a limited number of patients, to establish
dose.le~els and to obtain a preliminary estimate of efficacy (Phase 2 trials). Finally
s~dies m some thousands of patients are undertaken to establish efficacy. It is an
ax10~ among pharmacologists that one should get the drug into man as quickly as
poss1ble, but one must adhere to the pronouncement by the World Medical
Association's Declaration of Helsinki that: "Biomedical research involving human
subjects should be based on adequately performed laboratory and animal
experimentation."
It is .thus clear that the basic, premarketing establishment of the safety of a drug is
cru:ned ~ut in man. Notwithstanding that, some of the examples put forward by the

ammal nghts lobby are factually incorrect for more simple reasons.
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CHLORAMPHENICOL
"Animal tests fail to predict the effects of drugs with tragic consequences ...
Chloramphenicol ... passed as safe after animal tests - caused fatal blood
disorders."
Bitter Pills, NAVS leaflet
The fatal blood disorder caused by chloramphenicol is aplastic anaemia. It is rare for
the drug to cause this condition, lethality is reported as 1 in 76,000 (5). The rarity of the
reaction indicates that is an idiosyncrasy due to a genetic predisposition. It is thus not
surprising that the effect was not detected in the preclinical studies in humans. It is
absurd to suggest it should have been detected in animal toxicity tests.
PRACTOLOL
"Eraldin (practolol) .... Heart drug. Given to patients for four years before the
horrific effects were identified, these include blindness, stomach troubles, joint
pains and growths."
Bitter Pill, NAVS leaflet
Again, the reaction to practolol was idiosyncratic and was not detected until experience
with the drug had amounted to 250,000 patient years (6). Obviously, premarketing
studies in 5,000 to 10,000 patients would be unlikely to detect the toxic effects. The
animal toxicity tests, which are carried out simply to ensure that a novel drug has no
unexpected, acute toxic action, are irrelevant in this situation.
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Thus these reactions are due to idiosyncrasy, and no amount of animal
experimentation will ever ensure that people with an unusual genetic trait will not
have an untoward reaction .

I

I

ENTEROVIOFORM (CLIOQUINOL)
"All drugs are tested on animals and passed as safe for human use before they
reach market. But many have injured or killed people, eg clioquinol."
NAYS leaflet advertising World Day for Laboratory Animals
This drug is a particularly bad example for the NAVS. It was synthesized at the turn of
the century and soon used as a skin disinfectant to treat skin infection, then it was
used a mouthwash to treat mouth infections. It was thus a small step to swallow it to
treat infections of the lower bowel and diarrhea. It was used for this in the 1930s .
Clioquinol was thus never tested on animals before it was used in humans. When its
use for diarrhea spread to Japan, it was shown to cause subacute myelo-optic
neuropathy (SMON) (weakness paralysis, blurred visions, etc.). This prompted some
animal studies which showed that clioquinol produced neurotoxicity in frogs, mice
and rabbits (7). Moreover, there are two veterinary reports that show that clioquinol
given to cats and dogs to treat diarrhea in veterinary practice produced nervous
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disorders (8,9). Thus after the drug was shown to be toxic in humans, it was proved to
be also toxic in various species.
OSMOSIN
"Osmosin passed as safe after animal tests .... withdrawn 1983. Six hundred fifty
had side effects, and 20 died."
Bitter Pills, NAVS leaflet
Osmosin was not a new substance. It was a new formulation, that is, a new method of
preparation of indomethacin, a drug that had been in use since 1965. It was placed in a
capsule, with a laser-drilled hole in the end, in the hope that the indomethacin would
slowly leak out in the small intestine and not in the stomach and thus not cause
ulcers. Unfortunately, they did not test the capsule for effectiveness. It became sticky
in the gut, stuck to the side of the upper intestine and leaked its contents into a small
area of tissue. The drug and the potassium ions in the capsule had a necrotic action on
the mucosa (10).
Again, far from illustrating the invalidity of animal experimentation, these two
examples provide justification for the effectiveness of animal experiments in
safeguarding the welfare of the first human volunteers.
INSULIN
"Insulin produces (fetal) deformities in laboratory animals but not people."
Sharpe, R., Health With Humanity, ed. Mcivor BUAV, 1990
The suggestion that the naturally-occurring hormone insulin is teratogenic in
animals, but not in humans is so manifestly absurd that it is hard to reject that its
promulgation is not a deliberate deception. How can one argue that a naturallyoccurring hormone, variable concentrations of which are present in our blood at all
times, is per sea teratogen? If one examines the literature one sees that enormous
doses of insulin were given to animals, these doses sufficient to render them in a near
convulsive state for hours daily (11). The severe hypoglycemia produced caused fetal
abnormalities in the rabbits since the fetuses were starved of nutriment. The same
effects would be seen in women if they were so treated.
ASPIRIN
"Aspirin causes birth defects in rats and mice but not humans."
NAVS
The doses used to produce the birth defects are not discussed. When the original
papers are examined it can be seen that very large doses were used in the experimental
studies. Rats were given 300 mg/kg per day throughout the period of organogenesis
(12) or 250 mg/kg throughout pregnancy (13). This would be the equivalent to a 55kg
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woman taking 55 aspirin tablets per day for a least ten consecutive days during early
pregnancy or 46 tablets per day throughout pregnancy-doses that would never be
likely to be used in humans.
THALIDOMIDE
"Animal tests fail to predict the effects of drugs with tragic consequ:nces:Thalidomide. Sedative, used for morning sickness.. About 10,000 brrth defects
world-wide, and effects do not appear in most laboratory animals-so the
human tragedy could probably still occur."
Bitter Pills, NAVS
Thalidomide was never administered to pregnant animals before being marketed.
Five months after McBride's paper describing the alleged association be~een
.
administration of thalidomide and fetal abnormalities, a paper was pubhshed, also m
the Lancet, stating that thalidomide caused phocomelia in NZ white r~bbits, the most
common laboratory animal for the investigation of reproductive_phys10l<>9Y (14).
Subsequently, thalidomide was shown to be toxic to the embryo m rats, m1ce,
hamsters, marmosets, baboons, macaques and rhesus monkeys.
The basic testing of thalidomide on animals was poorly performed. Orallyadministered thalidomide was apparently non-toxic even when given in very large
amounts. No studies were undertaken however, to establish that the drug was
actually absorbed from the gut. In fact, it was not. The drug was simply being excreted
with the feces. This possibility was noted by Dr. Kelsey, of the FDA, who w~s
examining the application to market the drug in the USA. When respondmg to the
potential marketers of thalidomide she stated:
"The animal studies were not reported in sufficient detail, and the study of the
absorption of the drug in rats was not supported by evidence." (15, p.74)
Dr. Kelsey also stated that she would need evidence that thalidomide would be safe to
take during pregnancy (15, p.79).
A new formulation of thalidomide was produced by the German manufacturers, a
syrup suspension. The finely ground suspension of the thalidomide in this
preparation was absorbed and, when tested on animals by phar~~cologists ~ro~ the
British firm licensed to sell the drug, produced severe neurotox1c1ty. (At this time
there were reports of thalidomide producing peripheral neuritis in patients.)
The ultimate proof, if required, that thalidomide was ~ever tested ~n pregnant.
animals prior to marketing, comes from the defense rrused by the f1~ms marketing t~e
drug. They stated that it was not customary to do such tests at that time. !fowever, 1t
is likely that if they had followed the best drug testing procedures of the time, the
disaster may have been prevented.
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In Britain, these statements about thalidomide perpetrated by the A V propagandists

have been brought before the Advertising Standards Authority (ASA). The Council of
the ASA have considered all the evidence and sought appropriate advice and have
now decreed that leaflets and advertisements should no longer contain statements
suggesting that the thalidomide tragedy was caused by mistaken reliance on animal
experiments since the statement is "inaccurate and misleading."
I object to such statements of alleged "species differences" simply because they are

factually incorrect. However, if asked whether there are species differences in
reactions to drugs, it must be admitted that there are. But they are of no great
significance for there are great differences between human beings. Japanese people are
obviously particularly susceptible to clioquinol while 1 in 70,000 Caucasians suffer a
serious reaction to chloramphenicol due to idiosyncrasy.
I cannot blame members of the lay public for the general promulgation of

misstatements of fact. They wish to believe, and they take in good faith what they are
told by self-professed experts. I do however, blame those that mislead the lay public,
particularly if they assume a mantle of authority, such as being a scientific consultant
for an AR group or being a medical expert. Since many of these statements peddled
are easily exposed as incorrect after a desultory browse in a medical library, one can't
help but suppose that such experts are deliberately misleading the public by being
highly selective in the evidence they choose to produce.
This activity undoubtedly contributes to the hardening of the attitude of the
experimenter. But it has a more malign effect, for it generates an unjustified sense of
grievance in those that support animal experiments. This violence ranges from
pouring super glue into the door locks of charity shops (such as those of the Imperial
Cancer Research Fund), breaking such shop windows by catapulting large ball bearings,
and harassing the staff of such shops with loud hailers, through attempted murder by
the planting of bombs under the cars of scientists.
Whatever one's views on the moral question (which is certainly one that must be
addressed by us all), the facts should be sacrosanct. Misrepresentation should be
condemned.

DISCUSSION
Following Dr. Botting's presentation, he was asked if, in toxicity tests, it is not invalid
to overwhelm an organism's protective mechanisms with huge doses such as the
pumping of large amounts of aspirin into rats. The questioner added that these types
of tests usually seem to be discredited in the end due to the large doses used, to the fact
that animals respond differently, and to the fact that the same type of tests cannot be
done on humans. Dr. Botting agreed that standardization levels are often faulty and
that researchers can only do the best they can in adjusting for variables such as size and
metabolism. At this point it was mentioned that there is a massive effort to overturn
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the Delaney Clause that states if a substance shows any car~inogenic effect~ in anim~ls,
it cannot be used in humans. (Congress mandated saccharme as an exception to this
rule.)
One participant pointed out that in a General Accounting Office report on drugs
marketed between 1976 and 1985, 102 of 198 drugs either had to be withdrawn or
relabeled after full-scale use. It was pointed out the interpretation of data is influenced
by values- people holding different values can draw very different conclusions from
the same information.
The issue of the releasing of misinformation was briefly discussed and the comment
was made that it is wrong no matter which side does it. Often it is difficult to know
who is right and who is wrong. For example, is the Leader and Stark article or the
Stephens' article on the use of animals and alternatives by Nobel Prize winners
correct? Does it really matter if the articles draw different conclusions from the same
data set?
A participant stated that the Physicians' Desk Reference does not give a lot of comfort
to doctors in regard to the use of drugs during pregnancy, and that since tests have
"tightened up," some previously used drugs have been removed from the market
even though they were subjected to animal and human trials. Thus, researchers must
not be predicting toxicity very well. He went on to ask if we should not be questioning
why some new drugs exist and if they should even be tested. Dr. Botting replied that
every drug, given to some species, will show toxicity. Animal studies are only crude
toxic screens. He added, in r2sponse to a criticism of the post-marketing animal tests of
thalidomide, animal tests would have prevented the marketing of thalidomide if they
had been done correctly. The comment was then made that if medicines affect even
cats and dogs differently than humans, it seems that rats and mice must be very
different than humans. Are we not making huge leaps from animals to humans?
Another participant stated that the science community does admit that the
extrapolations from animal tests are inadequate.
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CONCLUDING DISCUSSION
Following the last presentation, the floor was opened for a general discussion with
all participants invited to speak.
The first participant addressed the issue of drug discovery and testing. He stated that
there is no doubt that pharmaceutical companies want to get their drugs into
humans. This was countered by the argument that a lot of drugs, however, never
reach the human stage because they either fail the toxicity study stage or fail the
clinical study stage. The reply to this was that this is what the pre-clinical studies are
designed to do--pick up the preliminary problems. The second speaker replied that
animal tests, however, may indicate a toxicity level that humans do not share so
"good" drugs may be kept out of the market while "bad" ones move on along the
testing line. Therefore, animal test results may not protect the first humans to take
the drug. A third participant observed that being the first human to take a drug
would always be risky whethPr the drug had been successfully tested on animals or
not.
It was observed that there is always a need to gather all possible information on a

drug to protect the first human volunteers. However, in "selling" an experiment,
there is often propaganda that implies that animal tests must be done and, if they
are done, that the result is a safe drug. However, this is not always true and no one
talks about the many drugs that fail the tests. Another participant added that, even
if some animal tests are of some value, it does not mean that they are then
necessary .
Referral was made to a new drug (FIAU), a viral-DNA inhibitor, that was given to
humans suffering from the hepatitis B virus after being tested on rodents and
rhesus monkeys. However, several of the human subjects suffered severe
complications and several died. The speaker went on to tell of an article in the
September, 1993, Journal of NIH Research, in which a Johns Hopkins clinician
testing a similar drug for HIV-1 infection stated, "You never know how relevant an
animal model is in predicting toxicity in humans." Another participant observed
that it is impossible to get 100% assurance from any human or animal test, and it is
difficult to figure out the acceptable levels of safety and ways to be sure that level is
always achieved .
During the discussion, one of the participants commented that he felt there was a
logical inconsistency to Dr. Rowan's "circular argument" (described in his talk). Dr.
Rowan stated that as approximately 40% of the research that has produced vaccines,
antibiotics, public health initiatives, etc. has used animals, it is reasonable to assume
that 40% of the credit should go to studies using animals. He went on, however, to
point out that it is not really possible to separate the various research approaches
when assigning credit as research tends to be an endless circle with insights flowing
from the clinic to the laboratory to the theoreticians and back again. If the flow is
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disrupted, much more than just the portion removed is lost. The participant argued
that 1) it is inconsistent to combine percentages with a circular analogy and 2) there
is not much exchange between clinical psychologists and the animal laboratories
and there has not been an enlarging of the knowledge base. He also felt that the
years spent by many psychologists doing animal studies to investigate conditioning
and other aspects of behaviorism have retarded the general knowledge base.
It was suggested that some of the psychology studies involving animal models have
proven to be of unexpected benefit to animals, especially farm animals. Another

participant replied that even in these studies there is most likely experimenter bias
wit~ the experimenter seeing what he/she wants to see. He expanded this thought
addmg that we are all taught our attitudes and that our degree of objectivity is based
on our learned attitudes and values. He concluded by pointing out that just because
something works doesn't mean it is necessarily good--the ends do not always justify
the means.
When Dr. Rowan was asked who is currently taking the lead in the debate, he
replied that there are few leaders, that there is very little serious debate going on,
and that the debate that exists is basically sterile and non-productive. He added that
it is important for all participants to understand the language used in the debate and
especially the assumptions and values behind the language.
Funding for research involving animals was briefly discussed. It was revealed that
one third of NIH funds go to research involving humans, one third to research
involving animals and one third to research using alternatives. In the United
Kingdom, 97% of the money from the top 15 medical charities goes to supporting
non-animal studies. One person questioned the amount of money spent on
developing and validating alternatives -- is it not unfair to demand the validation
of .al~ernatives when animal use is not validated? Another participant voiced the
opm10n that the NIH seems to be much more resistant to the use of alternatives
than private corporations.
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SUMMARY STATEMENT
Andrew N. Rowan
The debate over the utility of animal research is both factually complex and heavily
influenced by values. Where one person might see animal. testing o~ ne.w ~rug
entities as performing a useful function because the tests give some mdication of
potential side effects, another may view them as useless because such tests do ~ot
accurately predict all the likely problems with one hundred percent (or even nmety
percent?) accuracy. These proceedings provide an overview of one attempt to focus
the debate and to test one set of arguments- namely, those offering technical
criticisms or challenges drawn from philosophy of science to the standard view. that
animal reseatch has proved to be (very) important in the advancement of medical
and biological knowledge. All participants were sent the critique (developed b~
myself) of the arguments opposing animal research prior to the workshop but It
elicited relatively few comme:1ts during the course of the workshop.
Both Kaufman and Shapiro produced articulate arguments questioning the role
imputed to animal models for both the epistemology of biomedical research an~ in
the actual progress of biomedical knowledge. Despite the fact that those defendmg
the use of animals sometimes do, or appear to, imply that animal models provide
exact replicas of human biology and disease, it seems clear that this is an
exaggeration (in some cases, by considerable degree). However, it shoul~ also be
noted that differences between different animal species, and between arumals and
humans, have also proved to be very useful in helping biomedical science develop a
plausible and coherent picture of the way living organisms work.
Barnard delivered his usual polished promotion of the benefits of preventive
medicine and life-style changes. However, it was not possible to do more than
provide a brief overview of his slide presentation in these proceedings together with
the discussion. He did not address the issue that was raised in our critique of the
relevance of the existing knowledge base (based in part on animal research) in
current interpretations of clinical and epidemiological data to make
recommendations about prevention and life-style options today .
Stephens was the only commentator who devoted much attention to the critique
and to the other materials that were distributed to the participants prior to the
workshop. He expressed surprise that the handouts should have focused so much
criticism on the arguments of the animal activists rather than on the role and utility
of animal models in biomedical research. However, the aim of the workshop was to
examine the robustness of the arguments against animal research. Because of a
relative lack of detailed criticisms of the writings of animal activists from the
research community, the critique in these proceedings was developed to stimulate a
criticism and debate. As for the use of the Elizabeth Hughes narrative in the
example of the discovery of insulin (also criticized by Stephens), this was more than
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a simple appeal to emotions. The narrative provides important context to both the
social influences that drove diabetes researchers and also the reason why the
purification and distribution of insulin was perceived to be such a medical miracle
at the time.
Botting's address concentrated on problems he has identified in the attacks on
animal research presented in the animal protection literature. Botting is one of only
a handful of animal research advocates (others include Karl Nicoll, William Paton
and Ernest Verhetsel) who have begun to investigate carefully the claims made in
animal protection criticisms of animal research. He has called into question some
important claims in the animal research literature (e.g. if penicillin had been tested
on guinea pigs it would never have reached the market). Although Botting's
writings have been largely ignored by animal activists, they can only continue to do
so at the risk of seeing their public support begin to erode. It may be unfair, but
critics of the status quo usually have to keep themselves to a higher standard of
factual accuracy and interpretative analysis than those defending it.
In general, this workshop was successful. Although the debate about the merits of

the technical arguments against animal research was not really joined in the
workshop, and has not been since, these proceedings still represent the most
detailed look at the issue and provide a sampling of the more cogent and coherent
challenges to the idea of animal models and the value of animal research.
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